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Prefa ce
The National Aeronautics and Space Administration (NASA) has
been concerned with the potential toxicological hazards to humans that
may be associated with entering and living within spacecraft for pro-
longed periods. Despite major engineering advances in controlling the
atmosphere within spacecraft, some contamination of the air appears
inevitable. NASA has responded to this problem by measuring and
identifying numerous airborne contaminants during each space mis-
sion. As space missions increase in duration and complexity, ensuring
the health and well-being of individuals traveling and working in this
unique environment becomes increasingly uncertain.
As part of its attempt to establish a safe space environment, NASA
has requested that the National Research Council's Committee on
Toxicology (COT) develop appropriate guidelines for establishing
spacecraft maximum allowable concentrations (SMACs) for space-
station contaminants. SMACs are not intended to represent the
absolute dividing line between safe and unsafe exposures, because
certain individuals may respond differently. Short-term SMACs
provide guidance for crew members when it becomes necessary to
operate under emergency conditions lasting up to 24 hr. Such
exposures may produce measurable, but reversible, responses and
discomfort, but they should not interfere with or impair judgment.
Long-term SMACs are intended to avoid adverse health effects,
immediate and delayed, and to avoid degradation in performance from
continuous exposure.
In response to NASA's request, COT established the Subcommittee
on Guidelines for Developing Spacecraft Maximum Allowable
Concentrations for Space Station Contaminants. This subcommittee
was made up of scientists with expertise in toxicology, biochemistry,
epidemiology, pathology, analytical chemistry, industrial hygiene,
genetics, occupational medicine, biostatistics, and risk assessment.
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In establishing these guidelines, several major issues were con-
sidered, including the development of methods for (1) translating
existing animal toxicity data to predict toxicity for humans in space,
(2) evaluating the toxicity of complex mixtures, (3) modifying risk
estimates to account for altered physiological changes and stresses
caused by the microgravity environment of space, and (4) determining
how other exposure conditions within the spacecraft, such as
recirculation of air and water, lack of purging of expired air, activities
outside the space station, contamination from airlocks, reentry, and
radiation, may alter the predicted or expected response.
The subcommittee recognizes that many factors, such as the altera-
tions in normal human physiological and biochemical processes associ-
ated with spaceflight, are not fully understood and could warrant
revisions of proposed SMAC values. The subcommittee emphasizes
the necessity to review continuously and adjust these values when
additional scientific data become available.
This report could not have been produced without the untiring
efforts of the National Research Council staff: Beulah Bresler, senior
editorial assistant; Catherine Kubik, senior program assistant; and
Ruth E. Crossgrove, editor.
Finally, the subcommittee gratefully acknowledges the persistence,
patience, and expertise of Dr. Kulbir S. Bakshi, project director of the
subcommittee, and Dr. Richard D. Thomas, program director of COT,
in bringing this report to its final form.
Donald E. Gardner, Chairman
Subcommittee on Guidelines for Developing
Spacecraft Maximum Allowable Concentrations
for Space Station Contaminants
John DoulI, Chairman,
Committee on Toxicology
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Executive Summary
The National Aeronautics and Space Administration (NASA) is
preparing to launch a manned space station---Space Station
Freedom--by the mid-1990s. Because Space Station Freedom will be
a closed complex environment, some contamination of its atmosphere
is inevitable. Several hundred chemicals are likely to be found in the
closed atmosphere of the space station, most in very low con-
centrations. Important sources of atmospheric contaminants include
metabolic waste products of crew members and off-gassing of cabin
materials and equipment. Release of chemicals from experiments
performed on board the space station is also a possible source of con-
tamination, and the water reclamation system has the potential to
introduce novel compounds into the air. NASA is concerned about the
health, safety, and functional abilities of crews exposed to these con-
taminants.
This report, prepared by the Committee on Toxicology of the
National Research Council's Board on Environmental Studies and
Toxicology, is in response to a request from NASA for guidelines to
develop spacecraft maximum allowable concentrations (SMACs) for
space-station contaminants. SMACs are used to provide guidance on
allowable chemical exposures during normal operations and emergency
situations. Short-term SMACs refer to concentrations of airborne
substances (such as gas, vapor, or aerosol) that will not compromise the
performance of specific tasks during emergency conditions lasting up
to 24 hr. Exposure to 1- or 24-hr SMACs will not cause serious or
permanent effects but may cause reversible effects that do not impair
judgment or interfere with proper responses to emergencies such as
fires or accidental releases.
Long-term SMACs are intended to avoid adverse health effects
(either immediate or delayed) and to avoid degradation in crew per-
formance with continuous exposure in a closed space-station environ-
ment for as long as 180 days. Chemical accumulation, detoxification,
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excretion, and repair of toxic insults are thus important in determining
180-day SMACs.
ENVIRONMENTAL CONTROL AND LIFE-SUPPORT SYSTEM
The environmental control and life-support system (ECLSS) of the
space station is designed to control temperature, humidity, and com-
position of space-station air, including CO 2 removal; recover water;
dispose of waste; and detect and suppress fires. Fires are a great
potential hazard and much attention has been given to suppressing
them. A fire suppression system is available, but if all else fails, an
escape vehicle can be used. A subsystem of the ECLSS, the atmos-
phere revitalization system, which includes a mass spectrometer called
the major constituent analyzer, will analyze cabin air for 02, N2, H2,
CO, H_O, and CH 4 in all areas of the habitation and laboratory mod-
ules. A design criterion for the atmosphere revitalization subsystem
is the maintenance of space-station exposure levels below the 180-day
SMACs under normal conditions.
MODIFICATION OF CONTAMINANT TOXICITY
BY ENVIRONMENTAL FACTORS
The special conditions of the space environment must be taken into
account in defining spacecraft contaminant exposure limits. Deposi-
tion of particles is clearly different and lung function and the toxic
potential of inhaled particles may be different under microgravity
conditions than under full gravity conditions, as on earth.
Astronauts will be physically, physiologically, and psychologically
compromised for the following reasons: loss of muscle and bone mass,
altered immune system, cardiovascular changes, decreased red-blood-
cell mass, altered nutritional requirements, behavioral changes from
stress, fluid shift in the body, altered hormonal status, and altered
drug metabolism. These changes could be important factors in disease
susceptibility.
The physiological changes noted in spaceflight to date demonstrate
that the astronaut is in an altered homeostatic state and thus may be
more susceptible to toxic chemicals. How this altered state modifies
reactions to chemicals in the space-station environment is not fully
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known. The physiological changes induced in the space crew are
important and their impact must be taken into account in developing
SMAC values for various contaminants.
SOURCES AND TYPES OF DATA FOR
ESTABLISHMENT OF SMACs
The subcommittee recommends the use of data derived from a
number of sources in establishing SMAC values. These sources
provide information on a variety of health effects, including mortal-
ity, morbidity, clinical signs and symptoms, pulmonary effects, neuro-
behavioral effects, immunotoxicity, reproductive and developmental
toxicity, pathology, mutagenicity, carcinogenicity, and biochemical
and enzyme changes.
Chemical-Physical Characteristics of Toxicants
The chemical and physical characteristics of a substance provide
valuable information on potential tissue dosimetry of the compound
within the body and on its likely toxic effects. Preliminary estimates
of the toxic potential of new chemicals also may be derived from
known toxicities of structurally similar, well-investigated compounds.
However, additional uncertainty (safety) factors must be applied to
arrive at safe levels for those congeners that have no dose-response
data from intact animals.
In Vitro Toxicity Studies
Useful information can be obtained from studies conducted to
investigate adverse effects of chemicals on cellular or subcellular
systems in vitro. Systems in which toxicity data have been collected
include isolated organ systems, single-cell systems, and tissue cultures
from multicellular organisms maintained under defined conditions or
from functional units derived from whole cells. In vitro studies can
be used to elucidate the toxic effects of chemicals and to study their
mechanism of action.
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Animal Toxicity Studies
The data necessary to evaluate the relationship between exposure to
a toxic chemical and its effects on people are frequently not available
from human experience; therefore, animal toxicity studies must be
relied on to provide information on responses likely to occur in
humans.
The usefulness of animal data depends in part on the route of ex-
posure and species used. Although inhalation studies are most relevant
in assessing the toxicity of atmospheric contaminants, data from skin
absorption, ingestion, and parenteral studies are also useful. The
relevance of animal data to humans may be limited by the absence of
information on affected target organs and knowledge of metabolic
pathways and pharmacokinetics in animals and humans.
Clinical and Epidemiological Observations
In establishing SMACs for chemicals, dose-response data from
human exposure should be used whenever possible. Data from clinical
inhalation exposures are most useful because inhalation is the most
likely route of exposure. Human toxicity data also are available from
epidemiological studies of long-term industrial exposures, from short-
term high-level exposures following accidents, or from therapeutic
uses of some pharmaceutical agents. Some of these data provide a
basis for estimating a dose-response relationship.
Epidemiological studies have contributed to our knowledge of the
health effects of many airborne chemical hazards. The limitations of
epidemiology stem from its use of available data. The accuracy of
data on health outcomes varies with the source of the information, and
records documenting historical exposure levels are often sparse. For
example, mortality information derived from death certificates is
sometimes inaccurate, and exposure information collected for admin-
istrative purposes is limited. Despite these limitations, if the popula-
tions studied are large enough and have been exposed to high enough
doses over a sufficient period to allow for the expression of disease,
epidemiological studies usually provide valuable information on the
effects of exposure in humans without resorting to cross-species
extrapolation or to exposing humans in an experimental situation to
possible injuries from chemical hazards.
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Pharmacokinetics and Metabolism
Evaluation of the health effects of any chemical in a given environ-
ment is greatly facilitated by an understanding of its physiological
disposition in the body. Many chemicals require some form of
metabolic activation to exert their toxic effects. The formation of
reactive metabolites may depend on the level of exposure and the
pharmacokinetics of the chemical. Modern pharmacokinetic studies
can provide physiologically based models describing disposition of
chemicals within organs and tissues in the body. The space station is
a closed system with limited capacity to clear the air of chemical
vapors; the crew contributes to the removal of the chemicals from the
air through sequestration and metabolism.
Toxic metabolites may be highly reactive chemically. These metab-
olites are biologically reactive intermediates that may covalently bind
to nucleic acids or proteins that, in turn, may alter DNA replication
or transcription. In addition to formation of reactive metabolites,
metabolic activity also may lead to formation of species of active
oxygen that may damage nucleic acids or proteins or cause lipid
peroxidation. The resulting health effects may range from direct,
short-term target-organ toxicity to carcinogenesis.
Biological Markers
Biological markers are indicators of change within an organism that
link exposure to a chemical to subsequent development of adverse
health effects. Biological markers within an exposed individual can
indicate the degree of exposure to a pollutant and may provide
evidence of the initial structural, functional, or biochemical changes
induced by the exposure and, ultimately, the biochemical or physio-
logical changes associated with adverse health effects.
Biological markers can be divided into three classes:
1. Biological markers of exposure to pollutants may be thought of
as "footprints" that the chemical leaves behind upon interaction with
the body. Such markers contain the chemical itself or a metabolic
fragment of the chemical and thus are usually chemical-specific.
2. Biological markers of the effects of exposure include the totality
of subclinical and clinical signs of chemically induced disease states.
The markers of greatest interest are those that are early predictors of
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serious effects or late-occurring effects. Such markers would be use-
ful in determining what levels of pollutants in the space station can be
tolerated without causing irreversible deleterious health effects.
3. Biological markers of increased susceptibility to the effects of
exposure to pollutants could be used to predict which persons are most
likely to be at excess risk as space-station crew members.
RISK ASSESSMENT
(DEVELOPMENT OF EXPOSURE CRITERIA)
The assessment of toxicants that do not induce carcinogenic or
mutagenic effects traditionally has been based on the concept that an
adverse health effect will not occur below a certain level of exposure,
even if exposure continues over a lifetime. Given this assumption, a
reference dose intended to avoid toxic effects may be established by
dividing the no-observed-adverse-effect level by an appropriate
uncertainty factor or set of factors.
For carcinogenic effects, especially those known to be due to direct
mutagenic events, no threshold dose may exist. However, when car-
cinogenesis is due to epigenetic or nongenotoxic mechanisms, a
threshold dose may be considered. Attempts to estimate carcinogenic
risks associated with levels of exposure have involved fitting math-
ematical models to experimental data and extrapolating from these
models to predict risks at doses that are usually well below the experi-
mental range. The multistage model of Armitage and Doll is used
most frequently for low-dose extrapolation. According to multistage
theory, a malignant cancer cell develops from a single stem cell as a
result of a number of biological events (e.g., mutations) that must
occur in a specific order. Recently, a two-stage model that explicitly
provides for tissue growth and cell kinetics also has been used in car-
cinogenic risk assessment.
The multistage model, characterized by low-dose linearity, forms
the basis for setting SMACs for carcinogens. Low-dose linearity is
generally assumed for chemical carcinogens that act through direct
interaction with genetic material.
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ISSUES IN MAKING RECOMMENDATIONS FOR THE
ESTABLISHMENT OF SMACs
A number of issues need to be considered in developing recom-
mendations for establishing SMACs. These issues include (1)
translating animal toxicity data to predict toxicities in humans_ (2)
determining 30- or 180-day SMACs for carcinogens based on toxico-
logical or epidemiological studies that often involve long-term or
lifetime exposure_ (3)considering limits set by the Occupational Safety
and Health Administration, the American Conference of Govern-
mental Industrial Hygienists, and the National Research Council in
developing SMACs_ (4) evaluating the toxicities of mixtures_ and (5)
modifying risk assessments based on the altered environment in the
microgravity of space.

1 Introduction
The National Aeronautics and Space Administration (NASA) is
preparing to launch a manned space station by the year 1996. Because
of concerns about the health, safety, and functioning abilities of the
crews, NASA has requested that the National Research Council (NRC)
through the Board on Environmental Studies and Toxicology (BEST)
provide advice on toxicological matters for the space=station program.
The Subcommittee on Guidelines for Developing Spacecraft Maximum
Allowable Concentrations for Space Station Contaminants was es=
tablished by the Committee on Toxicology (COT) to address NASA's
concerns.
Spacecraft maximum allowable concentrations (SMACs) are defined
as the maximum concentrations of airborne substances (such as gas,
vapor, or aerosol) that will not cause adverse health effects, significant
discomfort, or degradation in crew performance. SMACs are further
classified into 1- or 24=hr emergency SMACs and 7-, 30=, or 180=day
continuous SMACs. The 1- or 24-hr SMACs are to be used in emer-
gency situations such as accidental spills or fire. The 7=, 30-, and
180=day SMACs are guidance levels intended to avoid adverse health
effects, either immediate or delayed, and to avoid degradation in per-
formance of crew after continuous exposure for as long as 180 days in
the space station; these values will be used for normal operations of
the space station. NASA expects that each crew for the space station
will stay aloft for up to 180 days. Limits for continuous exposure to
toxic substances for up to 1,000 days have been recommended for a
few chemicals by NRC (1968, 1972). However, the rationale for these
limits was not discussed in these reports. More recently, COT has
recommended exposure guidance levels for about 70 chemicals for up
to 90 days for crews of submarines (NRC, 1984a,b,c, 1985a,b, 1986a,
1987a, 1988a) with extensive documentation and rationale. In setting
7-, 30=, and 180-day SMACs for the space station, the subcommittee
will have to consider not only a longer exposure period but also the
I_.,..,..,_V.,_.--J I.IENItONALL_: _LA_I_
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physiological changes induced by the spaceflight and the susceptibility
of the crew to the effects of these changes. The subcommittee will
also consider the question of exposure to mixtures of chemicals
(approximately 300 substances have been identified that are expected
to be found in the space station).
The current space-station program began with President Reagan's
1984 State of the Union address in which he directed NASA to de-
velop a permanently manned space station within a decade. The space
station that NASA is now planning in response to this directive will be
353 feet long. It will be resuppliable and capable of staying in orbit
for about 30 years. Many of its systems will be highly automated,
leaving the crew more time for the tasks that can be performed only
by humans. The space station will be a multipurpose national research
facility with the following functions:
• A laboratory in which long-term research and technology devel-
opment studies can be conducted in the almost perfect vacuum and
microgravity of space.
• A manufacturing facility to make pure pharmaceuticals, perfect
crystals, and exotic metal alloys.
• A laboratory for life sciences research conducted in microgravity.
• A permanent observatory for earth or stellar viewing in low earth
orbit.
The space station will be continuously habitable; it will depend on
the space shuttle for launch and assembly as well as for crew rotation.
As currently planned, it will take nearly 20 space-shuttle flights to
assemble and outfit the space station in orbit. Initial plans call for a
crew of four persons in the permanently manned phase of the opera-
tional space station, supported by resupply and crew-rotation nights
of the space shuttle every 3 months. Wash water and condensate will
be purified and reused. Present planning calls for food and nitrogen
to be periodically resupplied from earth. Other materials to be
brought to the space station include oxygen to replace gradual loss
through leakage, raw materials for materials processing, and propel-
lants for engines needed to correct orbital decay; miscellaneous sup-
plies also will be brought up every few months.
The crew of the space station will live and operate primarily in four
(or more) pressurized modules. The U.S. laboratory and habitation
modules will be approximately 27 feet long and 15 feet in diameter.
The modules will be interconnected by resource nodes and various
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support structures. At PMC (permanently manned capability) the
pressure level inside will be the same as on earth (14.7 psi). The space
station will operate at an altitude between 150 and 270 nautical miles.
The space-station program involves international participation.
NASA has signed memoranda of understandings with Canada, the
European Space Agency, and Japan. These countries and space or-
ganizations will work with NASA to design and build some com-
ponents of the space station. Personnel from these countries also will
be included in the space-station crews. The Space Station Freedom
design currently comprises one module for habitation and three mod-
ules for laboratories. All four of the modules will be interconnected.
The space station will be an essentially closed and very complex
environment; therefore, some contamination of its atmosphere is inev-
itable. Several hundred chemicals have been found in samples of the
atmosphere from space-shuttle missions. Even more chemicals are
likely to be found in the space station. The contaminants come from
humans, from materials making up the spacecraft, from operation of
equipment, from the atmospheric gas supply, from food, from sup-
plies, from experiments or manufacturing activities on the space sta-
tion, and from reactions and interactions that occur between ordinarily
nontoxic constituents within a closed space. As manned space mis-
sions increase in duration, so will the severity and complexity of the
contamination problem and the necessity for control and removal of
these contaminants. Before an appropriate trace contaminant control
system can be designed, the generation of atmospheric contaminants
must be understood and their allowable exposure levels must be prop-
erly defined.
In response to NASA's request, this report was prepared to set forth
guidelines for establishing SMACs for up to 180 days for potential
atmospheric contaminants in the closed environments of the space
station. Where appropriate knowledge exists, these guidelines take
into account the pronounced physiological changes and stresses that
occur in microgravity environments during spaceflight and the behav-
ior of the contaminants under these conditions.
Some of the issues that should be addressed in developing these
guidelines include the following:
Q Converting animal or human toxicity data derived from in-
halation, oral, or parenteral exposures to human 1-hr, 24-hr, 7-day,
30-day, and 180-day SMACs.
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• Examining the issue of exposure to mixtures of chemicals (simul-
taneous exposure to approximately 300 chemicals) and proposing max-
imum exposure levels to these mixtures for the crew.
• Modifying the current methods for developing appropriate ex-
posure criteria by taking into account the pronounced physiological
changes and stresses that occur in the microgravity of space.
2
Historical Development of Limits
for Toxicants in Spacecraft
In 1968, at the request of NASA, the NRC's Space Science Board
organized the Panel on Air Standards for Manned Space Flight to
examine the likelihood of adverse effects from air contaminants on the
health or performance of spacecraft crews on prolonged missions and
to recommend limits for human exposure to spacecraft contaminants
under emergency conditions. Approximately 200 potential contamin-
ants of spacecraft atmosphere, identified from simulated spacecraft
studies and off-gassing experiments, were reviewed. Some of these
substances had already been examined by COT, and exposure limits
had been recommended for submarine atmospheres. The Space
Science Board panel recommended the acceptance of these limits for
90-day missions. From the 200 possible contaminants, the panel iden-
tified compounds having significant hazard potential for which no
submarine standards had been recommended and asked NASA to set
priorities for chemicals of primary concern. NASA identified 11
compounds for which they desired long-term exposure limits; NASA
also requested emergency limits for five compounds.
The recommended exposure limits were based on exhaustive anal-
yses of the toxicity literature on these compounds. The 90-day long-
term limits recommended were chosen with the objective of avoiding
(1) adverse health effects, either immediate or delayed, and (2) degra-
dation of performance. The 1-hr emergency limits were designed to
avoid significant degradation in crew performance in emergencies and
to avoid permanent injury; no safety factors were included, and tran-
sitory effects were considered acceptable.
The recommendations of this panel included (1) acceptance of the
90-day continuous exposure limits recommended by COT for 23 con-
taminants for 90-day submarine missions (Table l); (2) adoption of
limits, as provisional guidelines for spaceflight, for 11 contaminants
for 90-day and 1,000-day missions (Table 2); and (3) adoption of 60-
rain provisional emergency exposure limits (EELs) for five con-
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taminants in the event of a single accidental exposure during the mis-
sion (Table 3) (NRC, 1968). It should be noted that many of the
values in Tables 1-3 may be out of date because new toxicological data
have become available since they were originally developed.
TABLE 1 90-Day Contaminant Concentration Limit#
Contaminant 90-Day Limit, mg/m 3
Acetone 71
Acetylene 2,700
Ammonia 17
Benzene 3
Carbon monoxide 29
Clflorine 0.3
Dichlorodifluoromethane 5,000
1,1,2,2-Tetraflu oro- 1,2-dicldoroethane 7,000
Ethyl alcohol 115
Hydrogen 245
Hydrogen chloride 1.5
Hydrogen fluoride 0.1
Methane 3,300
Methyl alcohol 13
Methyl chloroform 3,000
Monoethanolamine 1
Nitrogen dioxide 1
Ozone 0.04
Phosgene 0.2
Sulfur dioxide 2.6
Toluene 188
1,1,1-Trichloroethane 1,100
Xylene 217
aAdapted from NRC (1968).
In 1971, NASA requested that COT review the exposure limits es-
tablished in 1968 by the Space Science Board (NRC, 1968) and set new
limits where appropriate. The new limits were of primary importance
to NASA in connection with providing engineering benchmarks to
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TABLE 2 Provisional Limits for Space-Cabin Contaminants for 90 and 1,000
Days a
Air Limit in mg/m 3
Contaminant 90 Days 1,000 Days
n-Butanol 30 30
2-Butanone 58 59
Carbon monoxide 17 17
Chloroform 24 5
Dichloromethane 105 21
Dioxane 36 7
Ethyl acetate 144 144
Formaldehyde 0.12 0.12
2-Methylbutanone 82 82
Tnchloroethylene 54 11
1,1,2-Trichloro, 161 No recommendation
1,2,2-trifluoroethane and
related congeners
aAdaptedfrom NRC (1968).
guide the development of advanced life-support systems for long-term
missions. COT established the Panel on Air Quality in Manned Space-
craft for this review, and provisional limits were recommended for 52
potential spacecraft contaminants for a variety of exposure durations
(Table 4) (NRC, 1972). The panel emphasized that each limit value
was provisional and subject to change as additional data became avail-
able. The panel also emphasized that these limits represented a maxi-
mum allowable concentration of a single contaminant without regard
to its occurrence in mixtures of contaminants. For toxicological as-
sessment of contaminant mixtures, the panel recommended the use of
a group-limit concept (for greater detail, see pages 91-92).
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TABLE 3 Provisional Emergency Limits for Space-Cabin Contaminants a'b
Contaminant Air Limit in mg/m 3 for 60 rain
2-Butanone 294
Carbonyl fluoride 67
Ethylene glycol 253
2-Methylbutanone 409
1,1_.-Trichloro, 1,612
1,2,2-trifluoroethane and
related congeners
aAdapted from NRC (1968).
bApplles to a single exposure during the mission.
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TABLE 4 Maximum Allowable Concentrations for Manned Spacecraft a
ppm (mg/m 3)
Compound 10 Min,
(Molecular Weight) Special 60 90 6
Area Min Days Mon Notes
ALCOHOLS
Methyl alcohol
(32.04)
Ethyl alcohol
(46.o7)
N-Butyl alcohol
(74.12)
Isobutyl alcohol
(74.12)
Sec butyl alcohol
(74.12)
Tertbutyl alcohol
(74.12)
n-Propyl alcohol
(eO.il)
Isopropyl alcohol
(60.il)
ESTERS
Methyl acetate
(74.0)
Ethyl acetate
(88.10)
Butyl acetate
(116.16)
Propyl acetate
(102.1)
-- 2OO 4O 4O
(26O) (52) (52)
2ooo 2,000 5o .50 b
(3,800) (3,800) (95) (95)
-- 200 40 40
(600) (120) (120)
-- 200 40 40
(600) (120) (120)
-- 200 40 40
(600) (120) (120)
-- 200 40 40
(6OO) (120) (120)
-- 200 40 40
(500) (120) (120)
400 200 40 40
(1,000) (500) (100) (100)
200 40 40
(600) (120) (120)
3O0 5O 5O
(1,080) (180) (180)
200 40 40
(940) (188) (188)
200 40 40
(840) (168) (168)
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TABLE 4 (Continued)
ppm (mg/m 3)
lO M_
Compound Special 60
(Molecular Weight) Area Min
9O
Days
6
Mon No[es
KETONES
Acetone
(58.o8)
Methylethylketone
cr2.1)
Methyl isobutylketone
Methylisopropyiket one
(86.77)
ALDEHYDES
Acetaldehyde
(44.o5)
Acrolein
(56.06)
Formaldehyde
(30.03)
ALICYCLIES
Cyclohexane
(82.14)
Cyclopentane
(70.13)
Methyl cyclohc_ne
(98.14)
Methyl cyclopentane
(84.1)
i
m
1,000
(2,400)
100
(:zoo)
100
100"
050)
50
(9O)
0.2
(0.5)
1.0
(1.0)
300
(1,0_)
(870)
500
(2,0OO)
3OO
(1,029)
30O
Cr2O)
2O
08)
2O
20*
(70)
10
(18)
0.1
(o.2)
0.1
(0.1)
60
(2O4)
60
(2O4)
15"
(60)
15"
(51)
300
(72O)
20
(SS)
20
20*
(7O)
10
(18)
0.1
(0.2)
0.1
(0.1)
60
(2O4)
6O
(2O4)
s
(60)
15"
(51)
b
C
d
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TABLE 4 (Continued)
Compound
(Molecular Weight)
ppm (mg/m s)
10 Min,
Sp_al 60 9o 6
Area Min Days Mon Notes
HALOGENATED ALIPATHICS
Chloroform
(119.39)
1,2-dichloroethane
(98.97)
Dichloromethane
(84.94)
Methyl cb_loroform
(133.4)
Tetrackloroethylene
(165.85)
R-11. Trichloroflouro-
methane (140.5)
R-12. Dichlorodiflouro- --
methane (124.0)
R-113. Trichlorotriflouro- --
ethane (192.5)
AROMATICS
Benzene
(78.11)
Ethyl benzene
(106.16)
Styrene
(io4.1)
Toluene
(92.1)
I00 5 5
(490) (24.5) (24.5)
200 10 10
(800) (40) (40)
100 25 25
(340) (87.5) (87.5)
300 50 50
(1,620) (270) (270)
100 5 5
(680) (34) (34)
5,000 100 100
(28,500) (570) (570)
5,000 100 100
(25,500) (510) (510)
5O0 50 50
(3,950) (395) (395)
100 1.0 1.0
(320) (3) (3)
2O0 20 20
(860) (86) (86)
50 10" 10"
(215) (43) (43)
200 20 20
(760) (76) (76)
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TABLE 4 (Continue, d)
ppm (mg/m 3)
10 Mm,
Compound Special 60 90
(Molecular Weight) Area Min Days
6
Mon Notes
AROMATICS (continued)
1,3,5-Trimet hylbenzene -- 25 3* 3*
(120.12) (123) (15) (15)
Xylene (o,m,p) -- 100 20 20
(106.12) (430) (86) (86)
HALOGENATED AROMATICS
Dichlorobenzene, -- 50 5 5
mixedo-andp- (300) (30) (30)
HETEROCYCUCS
1,4-Dioxane -- 100 5 5
(88.0) (360) (18) (18)
Furan -- 2 0.04 0.04
(68.07) (5) (0.1) (0.1)
Indole 1.0 1.0 0.1 0.1
(117.15) (4.8) (4.8) (0.5) (0.5)
Skatole 1.0 1.0 0.1 0.1
(131.1) (5) (5) (0.5) (0.5)
_WORGA_,'WICS
Ammonia 100 i00 25 25
(17.03) (70) (70) (17.5) (17.5)
Carbon dioxide 40,000 30,000 10,000 10,000
(44.01) (?2,000) (54,000) (18,000) (18,000)
Carbon monoxide -- 125 15 15
(28.01) (144) (17) (17)
Hydrogen chloride, gas -- 5.0 1.0 1.0
(36.46) (7.5) (1.5) (1.5)
g,h
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TABLE 4 (Continued)
ppm (mg/m 3)
10 Min,
Compound Speazial 60 90 6
('Molecular Weight) Area Min Days Mon Notes
INORGANICS (continued)
Hydrogen fluoride, gas -- 5.0 0.1 0.1
(20.0) (4) (0.08) (0.08)
Nitrogen dioxide -- 2.0 0.5 0.5
(46.01) (4) (1.0) (1.0)
Phosgene -- 0.5 0.05 0.05
(98.92) (2.0) (0.2) (0.2)
Sulfur dioxide -- 5.0 1.0 1.0
(64.1) (13) (3) (3)
MISCELLANEOUS
Acetronitrfle w 40 4.0 4.0
(41.05) (68) (6.8) (6.8)
Methylmercaptan 1.0 1.0 0.I 0.1 e
(48.1i) (2) (2) (0.2) (0.2)
aAdapted from NRC (1972).
bNot to be included in group limits.
CEstimated levels bear an asterisk; more inhalation data with animal models
would be desirable.
dBasod on eye irritation.
eLong-term limits based principally on odor.
fThese levels for dioxane are subject to drastic revision downward (< 1 ppm) if
future research proves that the compound is carcinogenic in animal models at
low (< 100 ppm) inhalation concentrations.
gThe 60-rain limit is based on a requirement that the carboxyhemoglobin level
not exceed 10%, assuming heavy-work activity (30 L/rain respiration) and
conformity to Coburn's equation. If the assumption of heavy-work activity _the
weightless situation proves unreal, then a value of 300 ppm (330 mg/m ) is
recommended.
hi'he mg/m 3 limits are also specified for the 70% 02, 30% N 2 atmosphere at
5 psia.

3
Sources of Space-Station
Contaminants
Many sources of atmospheric contaminants will be present in the
space station. Most sources will release only small amounts of material
into the air, but contaminants may build up during operation of a
closed vessel. Recognition of the many sources of atmospheric con-
tamination has helped in eliminating major sources of contaminants
and in developing methods to control and decrease contamination from
any source. Table 5 lists possible space-station contaminants (Leban
and Wagner, 1989). Major sources of contaminants include off-gas-
sing of cabin materials, components, and equipment and metabolic
waste products of crew members. All nonmetallic materials used in
the interior of the orbiter crew compartment are known to off-gas
contaminant compounds. These include cabin construction materials,
electrical insulation, paints, lubricants, adhesives, and degradation of
nonmetallic console and equipment structures. The heat produced by
equipment operation increases off-gassing. Minor sources of
contaminants in the spacecraft include internal decomposition of
hydraulic fluids, electrical equipment, plastics, oil, leakage from
environmental or flight control systems, volatile food components,
volatile components of personal hygiene articles, and reaction products
from the environmental control and life-support system (ECLSS).
Overheating of electrical components and fire can cause some struc-
tural materials (such as plastics) to emit toxic gases, vapors, and par-
ticulate matter. Pyrolysis of plastics generates a variety of contam-
inants, depending upon the composition of the polymer, including
hydrogen chloride, carbon monoxide, hydrocyanic acid, formal-
dehyde, and vinyl chloride.
All structural components and other materials to be carried on
board are tested to identify and quantify (under test conditions) off-
gassing compounds (NASA, 1991). Off-gassing rates for each com-
pound presented in Table 5 are based on these test results and on the
quantities of each material projected to be present in the space station.
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Escape of liquid or gaseouschemicalsfrom water reclamation,cool-
ing,and propellantsystems;combustion;thermaldecomposition;and
vaporizationcould lead to a major contaminationevent. For these
reasons,onlyammonia coolingloopsand hydrazinepropellantswillbe
permitted to be located outside the pressurized modules.
Complete and multiple containments of processing and experimental
apparatus are required by NASA if hazardous chemicals are present.
Nevertheless, the possibility of accidental release of chemical, radioac-
tive, or biological agents cannot be completely ruled out. Such re-
leases could produce serious contamination and high concentrations in
space-station air. Some of the commercial-type facilities expected to
be used could accidentally release a significant amount of chemicals.
In the space station, cleaning and degreasing agents, adhesives,
disinfectants, and lubricants will be used in cleaning and maintenance
procedures. Another potential source of contamination is repair of
metallic or plastic objects involving soldering, welding, or drilling.
These repair processes often involve localized heating and may release
toxic gases, vapors, or particles.
Chemical and physicalprocessesin cabin air involvingsunlight
(high-energysolarradiation)and some airbornecontaminants may
resultintheformationof highlytoxicchemicalssuch asozone,nitro-
gen dioxide,and otherphotochemicalproducts(peroxyacetylnitrate,
hydrogen peroxide,or freeradicals).The formationof such products
isacomplex, nonlinearfunctioninvolvingmany factorsincludingthe
intensityand spectraldistributionofsunlight,theconcentrationofthe
many precursors(aldehydesor carbon monoxide), the ratiobetween
organiccompounds and the oxidesof nitrogen,and the reactivityof
organic precursors. One resulting product, ozone, is highly toxic at
low concentrations, causing a number of pulmonary and extrapulmon-
ary effects. Due to the highly toxic nature of this gas, the potential
hazard associated with such exposure in the spacecraft environment is
a cause for significant concern.
The principal sources of contaminants from metabolic waste prod-
ucts of humans are urine, feces, flatus, and expired air. Animal urine
and dander are potential sources of contaminants; however, NASA
believes they are not a problem.
Urine will be a contaminant in the space station only if the design
is found to be ineffective in handling urine, leading to leakage or
spillage. Urinary contaminants would be only a nuisance; in the
absence of an infection of the urinary tract, urine is sterile.
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With feces, again the problem is proper mechanical and personal
handling. Experience in spaceflights has indicated that bowel regular-
ity (one or two stools per day) facilitates management. A method of
vacuum cleaning of air contaminants has been devised in addition to
surface cleaning.
Flatus is an appreciable source not only of periodic discomfort due
to odor but also of toxic gases, which must be removed from the cabin
air. As studied by Calloway (1971), flatus of men fed a low-residue
formula diet was 104 mL/12 hr (mean) in contrast to 286 mL/12 hr
from men fed a diet of processed foods similar to those given to astro-
nauts in the Gemini flight series. When gas-producing foods are eat-
en, flatus passage may increase to 60-120 mL/hr (Calloway, 1968).
Small volumes of flatus tend to have a composition like (ingested) air,
whereas large volumes contain more carbon dioxide and flammable
gases produced by bacteria, principally hydrogen and methane. These
gases, in addition to being expelled, are absorbed into the bloodstream
and then appear in expired air. Calloway and Murphy (1969), by
measuring both expired air and flatus, found potential total daily
volumes of 730 mL of hydrogen and 380 mL of methane in men on a
spaceflight-type diet. Although the investigators raised the possibility
that these amounts of hydrogen and methane "could constitute a fire
hazard in a closed chamber," it seems unlikely that, in the sizeable
space planned for the space station and with functional environmental
controls, concentrations of these compounds would be high enough for
risk of explosion. The malodorous compounds in flatus are indole,
skatole, mercaptans, ammonia, and hydrogen sulfide. The amounts of
these compounds and others in flatus depend on two principal factors,
the numbers and kinds of enteric organisms present and the substrate
for these bacteria provided by diet. The importance of minimizing the
number and amount of gas-producing foods for space diets is evident.
In any event, the atmosphere of the space station will be continually
cleansed.
The principal expired respiratory gas is carbon dioxide at 15-20
L/hr, though possibly as much as four or five times that in extrave-
hicular exertion (Calloway, 1971). Small amounts of carbon monox-
ide, hydrogen, methane, and ammonia are also expired.
Finally, skin cells are in a constant state of turnover, and there is a
constant daily flaking of desiccated dead-cell remnants. This dusty
material, though relatively minor in amount, would be a contaminant
if a regular washing and wiping routine were not followed by astro-
nauts in the space station. Studies of normal subjects (Calloway, 1971)
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have shown that several nitrogen-containing and organic compounds
and minerals are lost from the skin with insensible perspiration and
still more with active sweating. Measurements of actual losses from
the skin in space are limited to those taken on the Gemini VII space-
flight (Lutwak et al., 1969). Mineral losses were found to be minor
during this 14-day flight. Sweating was minimal, as would be
expected because most astronaut activities, although they require good
neuromuscular coordination, need little physical exertion except dur-
ing extravehicular operations. Since mineral and other losses from the
skin increase into the significant range only with active sweating, the
possibility of contamination from metabolic losses from the skin will
be reduced by minimizing the likelihood of sweating, presumably by
suitable temperature control and by moderation in physical activity.
There is a possibility of potential contamination from dust mites,
which produce proteins that are potent allergens. However, according
to NASA, dust mites have not proved to be a problem.
The water reclamation system in the space station may be a poten-
tial source of toxic chemicals in the cabin air. The system may con-
tribute several types of contaminants to space-station air.
1. Chemicals originally collected in the cabincondensate and then
revolatilized.
2. Components of hygiene wastewater.
3. Chemicals actually produced in water treatment.
Reclaimed water after treatment is the major source of drinking
water. Any chemicals present in the air will obviously be condensed
with water in proportion to their partial pressure and water solubility.
For most nonpolar volatile chemicals, cycling through the water sys-
tem is likely to contribute little to the hazards first encountered in the
air. On the other hand, chemicals that are both polar and volatile
(e.g., alcohols) may concentrate and even accumulate in the water
system. Under such circumstances, the major portion of the exposure
to the chemical may come via water.
Hygiene wastewater will contain soaps, detergents, and other chem-
icals present in personal hygiene products that might be expected from
showering and laundering clothing. Most of these chemicals are rela-
tively nonvolatile and unlikely to contaminate the air. These chemi-
cals are removed fairly efficiently by water treatment processes.
The water reclamation system has the potential to introduce novel
compounds into the air. The use of oxidants to disinfect and chemi-
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cally degrade water contaminants is the major means by which such
chemicals are produced. For example, the use of persulfate and sul-
furic acid to treat urine results in the generation of cyanogen chloride.
If this reaction product were to elude subsequent treatment processes,
it could introduce a sufficient amount into the confined space of the
shower to produce acute respiratory irritation. Repeated exposure to
such irritants over a 90- to 180-day period could have long-term ef-
fects. Similar but less well-defined problems might result from the
use of iodine (or other reactive chemical) as the residual disinfectant
in the water system.
Crews from several space-shuttle flights have reported eye and
respiratory tract irritation associated with the presence of airborne
particles and floating debris in the shuttle cabin. The debris included
paint chips, metal shavings, food particles, and fibrous materials,
including fibers from clothing, paper wipes, and fiberglass.
A panel assembled by NASA on Airborne Particulate Matter in
Spacecraft (NASA, 1988) recommended that particle concentration in
the cabin should be "as low as reasonably achievable" (ALARA). The
panel noted that simple technology could be used to discern the par-
ticle concentration in the atmosphere because the particles are likely
to have many of the characteristics of nuisance dust. The panel ques-
tioned whether the reported symptoms of eye and respiratory tract
irritation were due to those particles. The symptoms also could result
from exposure to gases such as nitrogen dioxide, ozone, or formalde-
hyde present in the air.
The recommendations of ALARA particle levels should allow, how-
ever, for design of appropriate particle-control technology. The panel
recommended the following numerical limits:
1. For flights of 1 week or less: 1 mg/m s limit for particles <10
/_m in AD (aerodynamic diameter) + 1 mg/m s for particles 10-100/_m
in AD.
2. For flights of >1 week and up to 6 months: 0.2 mg/m s for
particles 10-100 pm in AD.
No specific limit for particles >100 #m in AD was recommended
because adequate particle cleanup to meet the above values should
result in acceptable levels of larger particles.
In recommending these limits, the panel considered acute and
chronic irritation of the respiratory tract and eyes to be the primary
concerns. In selecting the 1-mg/m 3 limit for short flights, the panel
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considered that if the irritation reported was due to particles and not
gases, this limit should protect from irritation of the respiratory tract.
This exposure limit was based on data from exposure of healthy
humans to submicrometer-sized aerosols of sulfuric acid at concentra-
tions as high as I mg/m 8 with no signs of respiratory tract or eye ir-
ritation. The limit for nights of longer duration was lowered by a
factor of five to allow for the uncertainties about the toxicity of the
particles. The 0.2-mg/m s limit is the same as that set for U.S. sub-
marines where conditions are somewhat similar to spacecraft.
Obviously, exposure to chemicals from water and air are not neatly
separable problems. Therefore, it is important that assessments of
risks from certain concentrations of chemicals in air include consider-
ation of the potential risks associated with possible buildup of the
chemicals in the potable water system. Attention should be paid to
defining the toxic effects and exposure scenarios for chemicals that
are confined in the water system only.
Sources of contaminants have been categorized into three subgroups
according to predictability of release. Category 1 sources are those
that release contaminants continuously or frequently or are associated
with a specific routine activity. A principal characteristic of sources
in this category is that their contaminant-generation rates can be pre-
dicted with a high degree of accuracy. Systems usually can be de-
signed to keep exposures to compounds emitted from these sources at
or below the SMAC values. The emission rates given in Table 5 are
based on sources of this type.
Category 2 sources involve events such as inadvertent, accidental,
or emergency releases of contaminants. Events leading to such re-
leases include leaks, spills, failure of storage vessels, and overheating
of components. Contaminants that may be released from category 2
sources include all gases and liquids normally kept on the space station
and the thermal and chemical breakdown products of solid materials
(for example, electrical insulation). Unlike category 1 sources, poten-
tial release rates of category 2 sources cover many orders of magni-
tude, even for a single source. Thus, planning for control of such
releases involves examining various failure scenarios. Reliability anal-
ysis to establish the likelihood of failure events is an important step in
the risk assessment of contaminants from category 2.
Category 3 sources are those involving accidental release from ex-
periments performed on the space station. Some possible contaminants
may be identified by an examination of the manifests of the materials
for the experiments. Other contaminants may result from chemical
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reactions within an experimental module; recognition of such contam-
inants requires a detailed understanding of the module and the experi-
mental work or production to be carried out. Because every effort
will be made to eliminate releases from experimental modules through
the use of triple-containment systems, almost all releases from
category 3 sources, as from category 2, are likely to be accidental.
Unlike category 2, it is not possible to foresee with any certainty the
contaminants that may be released from these sources or the magni-
tude of release before space-station design and launch because many
experiments will be performed over the space station's lifetime. Novel
compounds may be released in the space station (e.g., new alloys or
crystals during water recycling). Evaluation of such compounds
usually will be required after identification because toxicity data on
new compounds frequently are not available.

4
Environmental Control and
Life-Support System
The environmental control and life-support system (ECLSS) is
designed to control the temperature, humidity, and composition of
space-station air; recover water; dispose of waste, and detect and
suppress fires. ECLSS consists of six subsystems: temperature and
humidity control (THC), atmosphere control and supply (ACS),
atmosphere revitalization subsystem (ARS), fire detection and
suppression (FDS), water recovery and management (WRM), and waste
management (WM). The first three subsystems are directly related to
the maintenance of cabin air quality.
The THC subsystem controls cabin air temperature, humidity, and
recirculation rate, as well as the exchange of air between modules and
equipment air cooling. This subsystem also includes food storage and
control of airborne particulates and microbes. Air temperature and
humidity are controlled by a condensing heat exchanger with auto-
matically controlled bypasses in each node and module of the station.
From a central location, the THC subsystem manages intermodule
ventilation, air exchange between pressured elements of the station to
maintain the proper total pressure and 02 and CO z partial pressures.
Particulate contaminants are to be controlled by drawing the cabin
atmosphere through filter elements that consist of 70-_m, hydrophilic,
pleated screens followed by dimple-pleated, borosilicate-fiber HEPA
filters. A protective metal grate collects much larger particles before
they enter the filter element.
The ACS subsystem will use stored O 3 and N 2 for contingency re-
pressurization and compensation for normal atmospheric leakage. The
ARS is intended to monitor and control the major components of air
(O z, N 2, H20, and COz) within the pressurized portions of the space
station. H 2, CO, and CH 4 concentrations also will be monitored. The
ARS functions consist of atmospheric monitoring, CO 2 removal, and
contaminant control. Removal of trace contaminants is to be accomp-
lished by the trace contaminant control subassembly (TCCS) that con-
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sists of a fixed activated charcoal bed, a high-temperature catalytic
oxidizer, and a lithium hydroxide bed. In the baseline subsystem, CO 2
will be removed by a four-bed molecular sieve.
CONTAMINANT CONTROL AND MONITORING
The schematic in Figure I shows the portions of the ECLSS devoted
to contaminant control for a single module. Air is to be circulated at
a relatively high rate through the cabins, and large debris and small
particles will be removed at each cabin's return air vent. Approxi-
mately 60% of this air stream will be recirculated back to the cabin
and 40% will pass through a condensing heat exchanger to remove
excess moisture. The condensate will be a source of potable water.
Assuming 100% removal efficiency and a module volume of 74.23 m s,
the TCCS has an equivalent dilution capacity of 0.21 air changes per
hour for contaminants removed by charcoal (at a charcoal-bed flow
rate of 15.29 mS/hr) and 0.06 air changes per hour for contaminants
removed by catalytic oxidation only (at an oxidizer flow rate of
4.25 mS/hr).
The ARS is designed to maintain exposures below the 180-day
SMACs for normal rates of contaminant generation when the station
is "permanently manned," and below the 30-day SMACs when the
station is only "man-tended." In addition, means are being devised to
reduce contaminant levels following unanticipated releases to meet the
1- and 24-hr SMACs, but these additional safety measures are not part
of the baseline design.
Air monitoring is critical to the functioning of the ACS subsystem
and the ARS (Humphries et al., 1990), not to mention to the astro-
nauts' health and safety. The ARS includes the major constituent
analyzer (MCA). This will be a mass spectrometer for analyzing cabin
air for 02, N2, H 2, CO 2, H20, and CH 4 in all pressurized areas of the
habitation and laboratory modules. Air samples will be drawn to the
MCA for analysis from seven locations sequentially. Each analysis
will require about 1 rain. Thus, measurements will be made at each
location approximately once every 8 rain. A separate instrument will
monitor CO by nondispersive infrared spectroscopy.
The ARS includes the atmospheric composition monitor assembly
(ACMA), which will measure trace contaminants, CO, total par-
ticulates, and the major atmospheric constituents listed above. Trace
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contaminants will be analyzed by gas chromatography/mass spectros-
copy. As in the MCA, the ACMA will bring air samples from pres-
surized areas to the central ECLSS analytical assembly. Each analysis
will require approximately 30 min, resulting in a monitoring frequen-
cy at each location of about once every 4 hr.
In addition to the analytical instrumentation in the ECLSS, the
toxicology subsystem of the environmental health system for crew
health care has extensive air-monitoring capability and also includes
dedicated continuous-monitoring instruments for total hydrocarbons,
hydrazine, HCI, HF, HCN, CO, and 30 targeted volatile organic
compounds.
RECOMMENDATIONS
Sources
Criteria for permitting materials on the space station should be
developed based on their physical, chemical, and toxicological proper-
ties and the ability of the ARS to limit their concentrations. If some
experiments utilizing substances that do not meet these criteria are
judged to be of such high priority that they should be performed on
the space station, the experimental modules should be subjected to
extensive testing, preferably in microgravity, to ensure complete con-
tainment. The subcommittee recommends development of instruments
for the continuous monitoring of contaminants of concern.
The subcommittee strongly recommends that the space-station de-
sign include the capability of isolating the laboratory modules from
other portions of the space station in the event of severe con-
tamination. Good design practices for laboratories on earth usually
include restricting air flow from the laboratory to adjoining non-
laboratory spaces by keeping the laboratory under negative pressure
with respect to those adjoining spaces. On the space station, however,
air will be flowing, by design, from the laboratory module to adjacent
nodes to maintain CO z levels and temperature and humidity control.
An additional consideration is that keeping the hatches open between
modules and nodes facilitates astronaut movement, creating more
efficient working conditions. Thus, the laboratory modules are not
isolated from the crew living quarters under normal conditions. Be-
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cause of the forced air exchange and open hatches, accidental release
of an acutely toxic material in the laboratory module could contamin-
ate air throughout the space station before measures could be taken to
close off the laboratory area. Some toxicants work so rapidly that
those exposed at high levels are incapable of donning their emergency
breathing apparatus.
In the current design, CO 2 is to be used as a fire suppressant. Halon
1301, an alternative agent used on the space shuttle, presents little
problem when air is only partially recirculated. It is not recommended
for complete recirculation because the ARS will remove chlorofluoro=
carbons only very slowly and may generate more toxic airborne con-
taminants. The subcommittee is concerned also that some products
generated by fires and by chemical fire extinguishers could rapidly
and severely compromise performance and impair the health of the
astronauts.
Rates of emission of contaminants have been estimated for
category 1 sources, i.e., those that emit contaminants continuously or
routinely. For sources in categories 2 and 3 (failure events and ac-
cidental releases from experimental modules), reliability analysis
should be performed to estimate the likelihood of release. For exam-
ple, overheating of an electrical component can lead to a high rate of
emission from electrical insulation. The probability of such events
should be estimated and the potential contaminants and release rates
determined. This information may then be incorporated in the risk
assessment. Appropriate countermeasures should be developed for
such events if the baseline ARS is shown to be inadequate.
Environmental Control and Life-Support System
The design criteria for the ARS have been driven largely by the
need for the control of contaminants from category 1 sources. The
primary concern has been to keep contaminants that are released con-
tinuously or frequently at acceptable levels. More consideration needs
to be given to control of contaminants from accidental releases. Based
on the volume of Lab=A module (74.23 mS), Figure 1 shows that about
one-fifth of the module's atmosphere passes through the TCCS in 1 hr.
Assuming 100% removal efficiency, a module volume of 74.23 m 3,
and the flow rates given in Figure I, the time required to achieve
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various fractional reductions in the concentrations after a sudden
release is shown below for contaminants removed by the charcoal bed
and for contaminants removed only by the catalytic oxidizer.
Fractional Reduction (C/Co)
Removal Time (hr)
Charcoal Catalytic Oxidizer
0.5 3.36 12.1
0.l I1.2 40.2
0.01 22.4 80.4
Thus, the TCCS seems to be inadequate to respond to an accidental
release of an acutely toxic chemical. NASA intends to develop meas-
ures to respond to sudden releases, but hardware for this purpose is
not part of the baseline station configuration. Consideration also
should be given to the alternative of increasing the capacity of the
TCCS as a means of responding to accidental releases. The design
criteria should take into account category 2 sources and the I- and
24-hr SMACs of contaminants released from these sources.
Another concern regarding the design of the ARS is the relative
locations of the dehumidification unit and the TCCS. Condensate
from the cabin atmosphere, although vented overboard during the
man-tended phase, will be used after treatment as potable water in the
permanently manned configuration. Air filters for removal of
particulate matter will be located upstream of the dehumidifier.
Nevertheless, the cabin air condensate is expected to contain numerous
volatile organic compounds that are either present as vapor in the
return air stream or vaporize from particulate material collected on the
filters. Condensate from space-shuttle missions has been shown to
contain a wide variety of organic contaminants.
Air Monitoring
Because of the high rateof air circulation,itis unlikelythat
personal(breathingzone)monitoring willyieldmuch betterestimates
of exposure than area monitoring, with the possibleexception of
exposuresexperienced by thoseworking very closeto a contaminant
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source. For those personnel,the use of passive air sampling or
biologicalmonitoring or both should be considered.
General
The dynamic mass-balance model of contaminant emission and
removal rates available at NASA should be used to predict the tem-
poral contaminant concentration profiles associated with all reasonably
probable emission scenarios. (Probable is defined by the Federal
Aviation Administration as an event having a probability of at least
10"S/flight-hr (FAA, 1988).) These scenarios should include low-level
continuous emissions, periodic releases, and abrupt high-level releases.
The concentration maximum and the l-hr, 24-hr, and 180-day time-
weighted averages could then be calculated from the hypothetical
concentration-time profiles and compared with the SMAC values.
This model should include humans as both sources and sinks.
Results of these tests could be used to identify the contaminants of
greatest concern and to take appropriate precautions. Continuous
monitoring, alarm systems, and emergency response procedures would
be required if exceeding a short-term limit (1 -hr SMAC) is reasonably
probable. Periodic air monitoring or biological monitoring or both as
well as deliberate response procedures would be sufficient for most
other contaminants. In addition, the use of the model in this manner
would help identify gaps in the current understanding of system
performance.
The overall plan for monitoring air contaminants, biological
monitoring of the crew, and complying with the SMAC values should
be developed by a team including industrial hygienists, physicians,
toxicologists, behavioral toxicologists, and health physicists, as well as
chemists and engineers.

5
Physiological Changes During
Spaceflight
The general physiological effects of exposure to microgravity are
better understood but much remains to be learned about the quan-
titative impact of physiological changes on susceptibility to chemicals.
Because a correlation appears to exist between the duration of expo-
sure and the frequency and intensity of the effects, the issues of dura-
tion of the spaceflights and of the microgravity environment remain
the critical variables in attempting to establish safe levels of exposure
to potentially toxic chemicals. Risk assessment of chemicals begins
with biological studies conducted in animals and humans on earth. It
is not clear how these data can be generalized to the space environ-
ment. A variety of assumptions will be necessary. The quality of
these assumptions can be substantially improved as more data from
astronauts and cosmonauts are obtained. To date, of the effects ob-
served in astronauts, space motion sickness and decreased immune
function seem to be the effects having the most direct relevance to
crew performance during spaceflights.
SPACE MOTION SICKNESS
Spatial disorientation and space motion sickness (SMS) occur early
in spaceflight. SMS has been described since the Apollo 9 flight in the
U.S. manned spaceflight program. The incidence of SMS among crew
members has ranged from about 35% during Apollo to 60% during
Skylab. During the four orbital flight tests of the shuttle, four of
eight crew members described symptoms of SMS.
SMS is a persistent operational medical problem and has been called
the most clinically significant medical phenomenon during the first
several days of spaceflight. SMS is characterized by increased sen-
sitivity to motion and head movements, headache, malaise, lethargy,
stomach awareness, loss of appetite, nausea, and episodic vomiting.
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Onset of symptoms usually occurs in the first 15 min to 6 hr of space-
fright, although delayed symptoms have been reported up to 48 hr into
the flight. Neural adaptive mechanisms respond, and within a few
days, the symptoms disappear. These mechanisms are not well under-
stood and further research is required. Symptom severity peaks during
the first 2 days of flight, and recovery is usually complete by the third
or fourth day. Results from the Soviet Salyut 6 flights show that
symptom resolution occurred after 3-7 days in space, but one crew
member reported having symptoms of SMS for 14 days.
The high incidence, severity, and duration of SMS have limited
some early flight crew activities. Extravehicular activity is now
scheduled after the third flight day to allow symptomatic crew
members to recover from SMS prior to extravehicular activity. A
minimum-duration flight lasts at least three flight days to ensure that
the crew has recovered sufficiently to permit all entry and landing
activities. Until successful countermeasures or accurate preflight
predictive tests can be developed, SMS will continue to have an impact
on crew activities during the relatively short 5- to 10-day flights of
the shuttle. The basic mechanisms of SMS should be defined so that
drug therapy or other techniques for reducing SMS can be developed.
BONE AND MINERAL METABOLISM
A variety of studies of human beings during long-term bed rest, of
humans in space, and of rats in space have shown that prolonged inac-
tivity and weightlessness result in both significant and continuing
losses of calcium from the skeleton and nitrogen from muscle and
decreases in mass of both rats and humans (NRC, 1988b; Whedon,
1984). These changes were consistent but quite different in degree
from subject to subject. In the longest bed-rest studies (7 months) and
in the longest orbital spaceflight during which metabolic measure-
ments were made (3 months), the rate of calcium loss was as great at
the end of the studies as it was soon after the start. In the severe
paralysis of poliomyelitis, calcium losses led to x-ray-visible os-
teoporosis in the bones of the lower extremities as early as 3 months
after paralysis. While the overall rate of calcium loss in Skylab astro-
nauts was 0.4% of total body calcium per month, the loss was es-
timated to be l0 times greater in the lower extremities than in the rest
of the body (based on bed-rest studies of calcium losses by metabolic
balance compared with decrease in bone calcium density). That loss
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could lead in 8 months of flight to a decrease in bone density in the
legs similar to that noted in paralytic poliomyelitis. In longer flights,
if mineral loss were to continue at a similar rate, the bones of the legs
might fracture during physical work in as little as 9-12 months, espe-
cially at gravities approaching 1 g. Studies of immobilized rabbits
showed marked decrease in strength of tendons and ligaments after
only 1 month. Thus, strains, sprains, and even ligament tears may be
more likely to occur and may occur earlier than bone fractures
(Whedon, 1984). These risks are not likely to affect crew performance
during flights,but they are seriousconsiderationson returnto earth
afterlong flightsor afterlandingon anotherplanet,such asMars.
The cellularmechanisms of minerallossare unknown. Excessex-
cretionof calcium associatedwith increasedhydroxyprolinein the
urineinhumans isindicativeof increasedbone resorption.Histologi-
calexaminationof thebones of theratson Cosmos showed suppressed
bone formation;itisdifficult,however, toapply theseresultsdirectly
to humans because of differencesinratbone physiology.
In more recentresearch,bed-reststudiesunder NASA sponsorship
have been continuedin searchof countermeasuresthatcould be ap-
pliedtoastronautsinspacetosuppressor preventcalciumloss(NRC,
1988b;Schneiderand McDonald, 1984). All mechanical procedures
testedthusfarhave been ineffectiveincludingexercisewiththe Exer
Genie pulleyapparatus,staticand intermittentcompression of the
lengthof the body from shouldersto feet,staticand intermittent
lower-body negativepressure,and impact loadingup to36 Ib tothe
bottom of the heel 40 times per minute for up to 8 hr daily. Cor-
relativeobservationshave indicatedthata procedurewould have tobe
derivedforuseinflightthatwould providean equivalentforceon the
skeletonof 4 hr of walking per day. A highcalcium and phosphorus
dietreduced calciumlossforup to90 daysonly;thereafter,increasing
fecalexcretionof calcium rendered a negativecalcium balance and
continued to do so for the remaining 17 weeks of the study. Sup-
plementarydietaryphosphatealonehad no lastingbeneficialeffectto
preventcalcium lossduringbed rest.Salmon calcitoninat I00 MRC
(Medical Research Council)unitsdailyalsodid not preventcalcium
loss. Promise in these countermeasure studieshas come from
bisphosphonatecompounds, such asdisodium etidronate,thatbind to
bone crystaland tend to inhibitbone resorption(Schneider and
McDonald, 1984).Countermeasure studiesarecontinuingparticularly
on the bisphosphonateleads.
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At the same time, with support from the National Institutes of
Health and other sources, various studies are being conducted on the
basic mechanisms of the effects of mechanical forces on bone dynam-
ics and development. Such studies may give insight into the bone-loss
problem in space. Conversely, development of effective counter-
measures to bone loss in space may contribute to improved therapy or
management of osteoporosis, which is characterized by gradually de-
creasing bone mass and strength and is the most prevalent clinical
disorder of bone.
As another mineral metabolic effect, hypercalciuria associated with
loss of mineral from bone in spaceflight might increase the potential
for stone formation in the urinary tract (NRC, 1988b). Although
75-80% of renal stones contain calcium, the possibility of stone for-
mation appears to depend not only on increased urinary concentration
of calcium but also on other factors such as urinary pH, concentrations
of inorganic elements (magnesium, potassium, and phosphorus), and
concentrations of organic compounds (uric acid, citrate, and oxalate).
Bed-rest studies have shown a slight rise in urinary pH and a lack of
change in urinary citrate, which in ambulatory states rises with in-
creases in urinary calcium (Deitrick et al., 1948). Both of these fac-
tors, if also noted in spaceflight, would favor decreased solubility of
calcium salts. These considerations suggest that research ought to be
continued on urinary-tract stone formation in relation to microgravity
as a significant possibility during long spaceflight. The likelihood of
such an occurrence may be small, especially if care is taken to main-
tain abundant urine volumes; nevertheless, such stone formation might
be catastrophic to health and function for the astronaut involved and
thus to success of the particular flight.
Potential toxicants having an adverse effect on bone that might be
introduced into the environment aboard the space station are alumi-
num and fluoride. Aluminum, a component of antiperspirants, could
be inhaled or absorbed through the skin and, if used in continuing
substantial quantities, could be deposited in bone and inhibit bone
formation. Fluoride has been under consideration as a possible in-
hibitor of bone resorption in weightlessness, but it should not be used
indiscriminately, because at only moderately high concentrations, its
incorporation into bone makes bones brittle and at increased risk of
fracture. Other cations and anions in the environment could have
adverse effects on calcium and bone metabolism.
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MUSCLE METABOLISM
After a few days of exposure to microgravity, the urinary excretion
of nitrogen compounds increases and muscle atrophy begins. These
effects may compromise the ability of astronauts to do their jobs.
They may not be able to withstand the stress of 1 g upon return to
earth; the continued excretion of nitrogen may have deleterious hor-
monal and nutritional effects. Exercise, diet, or drugs may ameliorate
these effects, but a fully effective treatment is not likely to be devel-
oped until impaired muscle function in prolonged microgravity is bet-
ter understood.
The increased urinary excretion of nitrogen by astronauts in Skylab
reflected muscle loss such as that observed during bed rest, but the
excretion was variable and generally greater than that seen during bed
rest. Most of the atrophy occurred in antigravity muscles, which are
no longer load-bearing.
In all nine Skylab astronauts, the high level of nitrogen excretion
continued unabated for the duration of the flight (up to 84 days)
(Whedon et al., 1974). This response indicates a serious malfunction
not likely to reach a new steady state until an extreme degree of atro-
phy is reached. The nitrogen loss was accompanied by losses of
15-30% of muscle mass and strength in the lower extremities. The
considerable exercise activity of the astronauts in Skylab 4 resulted in
somewhat lesser losses of muscle mass and strength than on earlier
flights but was obviously not fully protective.
Although the mechanism of the process of atrophy remains un-
known, certain aspects have become evident (NRC, 1988b). Muscle
atrophy is accompanied by decreased synthesis of muscle protein and
by some degree of increased degradation. As shown in rats that are
suspended (hind limb unloaded), loading and stretching of otherwise
inactive leg muscles prevented muscle atrophy and stimulated protein
synthesis; the addition of electrical stimulation increased protein syn-
thesis markedly. As shown in muscle cultures, stretching stimulates
protein synthesis.
The uncertain value of physical exercise for suppressing muscle
atrophy during spaceflight has been noted previously; no controlled
studies of exercise in flight have been attempted.
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CARDIOVASCULAR FUNCTION AND BODY FLUID CHANGES
In the Space Science Board's publication Life Beyond the Earth's
Environment (NRC, 1979), the Cardiovascular Panel summarized their
review of studies up to that date in this area of space physiology as
follows:
The experience hitherto gained from manned slmceflight demonstrates that the
cardiovascular system can adapt promptly to weightlessness and that man can
maintain an excellent functional capacity in space for prolonged periods of time.
However, an impressive body of data indicates that sudden exposure to 0 g is
associated with a rapid shift of a considerable amount of interstitial fluid and
blood from the lower toward the cephalad parts of the body. Most of the tranv
located fluid is accommodated in the intrathoracic compartment, distending its
vascular structures and presumably inducing significant changes in central hemp-
dynamics. The increase of the intrathoracic blood volume is apparently
"interpreted n by the body as a "total body _ intravascular volume expansion and
elicits compensatory mechanisms (i.e., natrinresis and diuresis), which reduce
total blood volume. The lack of any impairment in inflight physical work (aero-
bic) capacity indicates that the contracted blood volume is an appropriate adap-
tation to the zero environment. However, this adaptation becomes inap-
propriate upon return to normal gravity. Postflight circulatory studies demon-
strate decreased orthostatic tolerance, decreased physical work capacity, and
lowered exercise stroke volume and cardiac output in the sitting position. All
of these postflight phenomena are consistent with a state of relative hypo-
volemla.
The fluid shift from the legs into the thorax as seen in Skylab
crew members occurred within the first few days of flight and
amounted to more than 2 L of extravascular fluid, as determined by
a series of accurately located limb-girth measurements (Thornton et
al., 1974). Related Skylab studies showed an apparent increase in leg
venous compliance during the first 2 weeks of flight and a later
decrease thought to be primarily related to the decrease in leg
musculature (Thornton and Hoffler, 1974). In addition to the
apparent decrease in plasma volume in weightlessness, red-blood-cell
volume in Skylab crew members decreased by a mean of 11%, or
232 mL. Although some hemolysis occurred in Gemini astronauts,
neither hemolysis nor hemorrhage occurred in Skylab members, and
current interpretation is that splenic entrapment associated with slight
inhibition of bone-marrow red-blood-cell formation occurred, as
indicated by an observed decrease in reticulocyte counts (Johnson et
al., 1974).
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IMMUNE SYSTEM
Although reports to date are conflicting, some indicate that a
microgravity environment may alter the immune system's function.
Cogoli et al. (1980) reported that cultures of human lymphocytes sub-
jected to microgravity responded to concanavalin A, a lymphocyte-
stimulating agent, 97% less frequently than ground-based controls did.
Studies of the astronauts of the first four space-travel-system flights
revealed that the lymphocyte responses to phytohemagglutinin,
another lymphocyte-stimulating agent, were reduced by 18-61% of
normal following spaceflight (Taylor and Dardano, 1983). Stress has
been suggested as the cause of these changes, but that cause has not
been established and should be studied further.
In an unmanned Russian spaceflight, the weights of lymph nodes
and spleens of rats flown for 22 days were reported to be markedly
reduced, compared with those of controls on earth, because of a
marked decrease of lymphocytes in these organs. The effects were
found to be reversible since the organs returned to normal 27 days
postflight (Durnova et al., 1977). In another study, Mandel and Balish
(1977) studied rats subjected to a 20-day flight aboard the unmanned
U.S.S.R.-Cosmos 7820. They immunized groups of rats with
formalin-killed Listeria monocytogenes 5 days before flight and
compared animals exposed to space conditions with l-g controls.
They concluded that no deterioration of the acquired cell-mediated
immunity to L. monocytogenes could be detected in flown rats.
NUTRITION
Prior to the start of the spaceflight program, there was speculation
that decreased effort of movement in weightlessness would result in
diminished caloric requirements compared with those on earth. Diets
were actually planned, however, at caloric levels close to those needed
for normal activity on earth. In practice this procedure has worked
reasonably well. In the 1- to 3-month flights of Skylab, modest loss
of body weight occurred, associated with body-fluid shifts and losses
in muscle mass, as astronauts consumed 2,400-2,800 calories per day.
Clearly, caloric requirements were not lessened in space (NRC,
1988b).
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In the past, many athletes and astronauts have been convinced that
high intake of protein builds muscle and strength. However, the
physiological evidence indicates that protein is increased in muscle
only when needed for the muscle hypertrophy required by continuing
physical activity; excess calories of any kind are converted to and
stored in the body as fat. In addition, numerous studies unrelated to
space have indicated that increasing the protein intake increases the
urinary excretion of calcium. The level of protein in the diets of
astronauts, therefore, should be reconsidered because of its potential
relationship to urinary tract stone formation and, possibly, loss of
minerals from the skeleton. The high phosphate content of meat may
partially protect against the effect of high protein intake increasing
urinary calcium. At the same time, the negative nitrogen balance
associated with muscle atrophy in weightlessness should not be accen-
tuated by encouraging too low a protein intake. Since negative nitro-
gen balance in space has occurred at daily protein intakes of 85-95 g,
the recommended intake should not fall below this level (NRC,
1988b).
Carbohydrates should be of special concern because of their effects
on behavior. Abundant evidence supports the view that any dietary
carbohydrate that elicits the secretion of insulin can increase the syn-
thesis and release of the brain neurotransmitter serotonin unless con-
sumed with adequate amounts of protein. This substance makes
people drowsy and interferes with optimal performance. If this rela-
tionship is not recognized, menus and the time of consumption of
particular items--especially snacks--might not be appropriate for the
tasks required, particularly if they are complex and prolonged. It is
possible that other food constituents will be found that affect behav-
ior, mood, and cognition (NRC, 1988b).
Among the countermeasures tested by NASA have been high in-
takes of calcium and phosphorus by bed-rest subjects. The study
showed that this procedure maintained calcium intake and excretion
level in balance for up to 3 months, after which the gradually rising
fecal excretion of calcium caused a negative calcium balance. Hence,
there is no basis at this time for recommending calcium intake during
spaceflight at a higher level than 1,000 mg/day. It is obvious, how-
ever, that a low intake of calcium favors loss of this mineral from the
skeleton, adding to the deleterious effect of microgravity. Therefore,
the recommendation of the Life Sciences Task Group of the Space
Science Board is 1,000 rag/day (NRC, 1988b).
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Bed-rest studies of the effects of high intake of phosphorus showed
some suppression of the tendency of urinary calcium to elevate, but
overall phosphorus intake manipulation was ineffective because of
gradually increasing fecal calcium excretion. Furthermore, the pos-
sible deleterious effect of phosphorus intake higher than an ap-
proximate calcium/phosphorus ratio of 1:1.8 must be remembered.
Too high an intake of phosphorus will exert some binding effect on
calcium in the intestine and tend to inhibit calcium absorption.
Since no studies have been done on the effects of spaceflight on the
metabolism of any of the trace elements, no comment can be made
other than that care should be taken that space diets contain trace
elements in the amounts recommended in the U.S. Recommended
Dietary Allowances (RDAs).
The important vitamin in long spaceflights is vitamin D. Enclosure
in a space vehicle will prevent the normal conversion in the skin of the
vitamin D precursor to vitamin D. Conversion is normally ac-
complished by exposure of the face and arms to as little as 20-30 rain
of sunlight a day. Since vitamin D is essential for facilitating calcium
absorption from the intestine, as well as other calcium-related effects
in kidney and bone, this vitamin will need to be supplied to space
travelers. However, amounts should not exceed 800-1,000 IU/day
(Holick, 1986). The RDA of vitamin D is 200 IU (5 /_g) (NRC,
1989a); however, there is evidence that in the absence of any exposure
to sunlight, the RDA for healthy young adults, such as astronauts, is
closer to 600 IU (15/_g) (Holick, 1987).
The lighting environment, including the spectral distribution and
intensity of the lighting, needs to be carefully engineered for the space
station. Adding a small component of UVB (290-320 nm) radiation
in an area where astronauts exercise or eat would promote vitamin D
in the skin. The intensity of the lighting also should be evaluated to
help maintain the biological clock and decrease the incidence of
"seasonal affective disorder syndrome."
Other vitamins are not as critical since adequate amounts will be
taken in the diet provided it is balanced and the vitamins are not de-
graded by the methods of food preservation in use. It has become
customary, however, to provide astronauts with daily vitamin supple-
ments at RDA levels, which is a reasonable procedure.
In the early days of planning for manned spaceflight, many thought
that diets should be low in residue so that bowel movements would be
small and infrequent. However, bowel function in microgravity, espe-
cially in longer flights, was observed to be essentially normal. Hence,
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diets should be normal in residue, and adequate bulk should be avail-
able to afford relatively easy passage of stools once or twice a day.
With regard to research and development at the practical level, the
acceptability of various currently available packaged, canned, freeze-
dried, or heat-stable food items should be evaluated for spaceflights
extending many months to years. Because the capacity to carry and
store frozen food items is likely to be limited in extremely long
flights, research in space-food technology should be revived in plan-
ning for the space-station era. To date, nutrition investigations
(unrelated to space) suggest that individuals do not crave a continuous
variety of foods, but rather they tend to select from a small range or
limited number of foods over a period of months, and these periods
continue throughout life. Reduction in the total list of available food
items should simplify both the strategy of storage of multiple food
packages in a long-flying spacecraft and the ability of travelers to
retrieve desired items with a minimum of difficulty and time. The
space station will need to provide for testing of currently available and
newly formulated items for long-term durability and acceptability.
6
Establishment of Spacecraft
Maximum Allowable
Concentrations
DESCRIPTION OF SMACs
Spacecraft maximum allowable concentrations are used as guidance
for chemical exposure, either during normal operations of the space-
craft or during emergency situations. A 1- or 24-hr SMAC is defined
as a concentration of a substance in air (such as a gas, vapor, or
aerosol) that may be acceptable for the performance of specific tasks
during emergency conditions lasting for periods of less than 1 hr or
less than 24 hr. The effects of an exposure at a 1- or 24-hr SMAC
could include reversible effects that do not impair judgment and do
not interfere with proper responses to the emergency. The kinds of
emergency exposures anticipated could result from events such as
fires, spills, or line breaks.
The 1- and 24-hr SMACs are acceptable only in an emergency
when some risks or some discomfort must be endured to prevent
greater risks (such as fire, explosion, or massive release). Even in an
emergency, exposure should be limited to a defined short period.
Exposure at the 1- and 24-hr SMACs might produce such effects as
increased respiratory rate from increased carbon dioxide, headache or
mild central nervous system effects from carbon monoxide, and res-
piratory tract or eye irritation from ammonia or sulfur dioxide. The
1- and 24-hr SMACs are exposure levels that should not cause serious
or permanent effects. While minor reduction in performance is per-
missible, it should not be so much as to prevent proper responses to
the emergency (such as shutting off a valve, closing a hatch, removing
a source of heat or ignition, or using a fire extinguisher). For exam-
ple, in normal work conditions, a degree of upper respiratory tract
irritation or eye irritation causing discomfort would not be considered
acceptable; during an emergency, such an effect would be acceptable
if it did not cause irreversible harm or seriously affect judgment or
performance.
59
GUIDEL,INE$ FOR DEVELOPING S_I_4C$
SMACs for up to 180 days are concentrations designed to avoid
adverse health effects, either immediate or delayed, and to avoid deg-
radation in performance of crew after continuous exposure. In con-
trast to I- or 24-hr SMACs, which are intended to guide exposures
during emergencies (exposures that, although not acceptable under
normal operating conditions, should not cause serious or permanent
effects), 180-day SMACs are intended to provide guidance for opera-
tions lasting up to 180 days in an environment like that of a space
station. Accumulation, detoxification, excretion, and repair are im-
portant in determining 180-day SMACs. If a material is cumulative
in its effects, its 1SO-day SMAC must take that into account. Neuro-
pathological regeneration or repair of toxic injuries occurs more readi-
ly in intermittent exposures than in continuous exposure to constant
toxic insult. Therefore, repair is important in the recommendation of
180-day SMACs.
SOURCES OF DATA FOR DEVELOPING SMACs
Various types of evidence should be assessed in establishing SMAC
values. These include information from ( I ) chemical-physical charac-
terizations of the potential toxicant, (2) in vitro toxicity studies, (3)
animal toxicity studies, (4) human clinical studies, and (5) epidemio-
logical studies.
Chemical-Physical Characteristics of Toxicant
The chemical and physical characteristics of a chemical provide
valuable information on the dosimetry of the compound within the
body and on the likely toxic effects. For example, size and water
solubility of inhaled particles strongly influence where the material
deposits in the respiratory tract. Likewise, lipophilicity influences
absorption of the material where it accumulates and how long it re-
mains in the body. Structure-activity relationships may allow esti-
mation of the toxic potential of new compounds based on the known
toxicities of well-investigated structurally related compounds. How-
ever, additional uncertainty (safety) factors must be applied to arrive
at safe levels for those congeners that have no dose-response data from
intact animals.
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In Vitro Toxicity Studies
Important data can be obtained from studies that investigate
adverse effects of chemicals on cellular or subeellular systems in vitro.
Systems in which toxicity data have been collected include isolated
organ systems (e.g., isolated perfused livers and lungs), single-cell
organisms including bacteria, cells isolated from specific organs of
multicellular organisms and maintained under defined conditions (e.g.,
isolated hepatocytes and bone-marrow colony-forming units), func-
tional units derived from whole cells (e.g., organized subcellular par-
ticles including nuclei and mitochondria), breakdown products of cel-
lular disruption (e.g., microsomes and submitochondrial particles),
isolated or reconstituted enzyme systems, and specific macromolecules
(e.g., proteins and nucleic acids).
Data on inhibition of specific physiological functions, pathological
outcomes of exposure, genetic damage, changes in xenobiotic metabo-
lism, or changes in levels or quality of cellular components can con-
tribute to these evaluations. In vitro studies can help both to describe
the effects of chemicals and to provide information on the mechanism
of action of chemicals.
In vitro systems are used on the assumption that the effects ob-
served present a reasonable model for humans. In the current context,
the additional caveat that they should reflect the response of humans
in space must be added. Therefore, use of older data and plans to
collect new data should pay heed to the need for surrogate modeling
relevant to the astronaut.
Animal Toxicity Studies
The data necessary to evaluate the relationship between exposure to
a pollutant and its effects on a population are frequently not available
from human experience. For many air pollutants, studies in animals
have provided the only useful data. Ideally, the data should be de-
rived from at least two species and by the inhalation route.
Inhalation experiments with animals provide a basis for estimating
possible effects in humans and the concentrations at which these ef-
fects occur. They are useful in the identification of adaptations that
may occur following repeated exposure. They permit the testing of
hypotheses about the mechanism of the toxic action of pollutants.
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They offer a good opportunity to explore interactions between pol-
lutants and other factors that may affect toxicity.
Data from skin absorption, ingestion, and parenteral studies are also
potentially useful. Since eye irritation can be debilitating, eye-irritan-
cy testing of substances found in space-station air also is needed. The
usefulness of animal data depends in part on the species used. Rele-
vance to humans may be limited in the absence of information on tar-
get organs and pharmacokinetics in both animals and humans.
The better animal studies will report the following:
• The most sensitive target organ(s) or body system(s) affected by
exposure to the contaminant in question.
• The nature of the effect on the target organ(s).
• Data to establish dose-response relationships for the target
organs(s)--from no effect to severe effects. (The distinction between
exposure and dose needs to be made.)
• The rate of recovery from reversible effects, if any.
• The nature and severity of injury for effects that are not revers-
ible.
• Cumulative effects, if any, such as neurotoxicity and cancer.
• Pharmacokinetic data for comparison with data obtained from
humans.
• The effects of interaction, if any, of the toxicant with other air
pollutants (or exposure conditions) and the minimum concentrations
at which the interaction appears to occur.
• Techniques used to assure quality and avoid bias.
Classic toxicity studies employ normal animals. It may be necessary
to develop animal models with features similar to the physiological
state of the astronaut in prolonged spaceflight. Although such models
are approximations to the human condition, they should provide better
information than studies on unaltered normal animals. Thus, animals
flown in the space shuttle or the space station are likely to be more
appropriate surrogates for humans. For example, rats flown aboard
Cosmos 1887 showed altered hepatic function. These rats also demon-
strated skeletal muscle weakness resulting from muscle fiber atrophy
and segmental necrosis. Studies of the myocardium showed evidence
of atrophy.
In addition to the microgravity of space, animals can also be ex-
posed to launch and reentry gravity forces, noise, and vibration.
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Clinical Studies
In establishing SMACs for chemicals, dose-response data from
human exposure are most desirable, and such data should be used
whenever possible. Experimental human studies can be designed to
provide useful information on dose-response relationships. Ethical
concerns limit these studies to pollutants that are anticipated to have
no residual effects consequent to the experimental exposure and to
short-term studies. Data from inhalation exposures are most useful
here, because inhalation is the most likely route of exposure.
Epidemioiogical Observations
Human toxicity data frequently are obtained from epidemiological
studies of long-term industrial exposures as well as short-term
exposures usually to high levels of toxicants following accidents.
These data sometimes provide a basis for estimating a dose-response
relationship.
Epidemiological studies have contributed to our knowledge of the
health effects of many airborne chemical hazards, for example, radon
daughters (Whittemore and McMillan, 1983) and vinyl chloride
(Waxweiler et al., 1976). Studies of environmental and occupational
exposure can assess acute effects of short-term exposure such as myo-
cardial infarction after exposure to methylene chloride (Stewart and
Hake, 1976) or effects of long-term exposures such as cardiovascular
disease associated with long-term exposure to carbon monoxide (Stern
et al., 1988). One limitation of most epidemiological studies is the
limited information that is available about past exposure (Checkoway
et al., 1989). Studies that include estimates of past exposure based on
available historical exposure records, either of the work environment
or personal samples, tend to be more useful than those based on years
of employment (Rinsky, 1989). Studies that involve assessment of
exposure that occurs while the cohort is followed are likely to provide
more reliable information on exposure because the sampling scheme
can be devised as part of the research plan rather than relying on
available data collected for other purposes, such as assessing compli-
ance with exposure regulations (Smith, 1987). However, an appealing
aspect of retrospective studies is that the exposure, the interval be-
tween exposure and onset of disease, and the onset of disease will have
occurred by the time the study is conducted; in prospective studies,
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time must pass for any responses to occur. Epidemiological studies
also vary in the accuracy and precision of the health outcome meas-
ured. Some of these outcomes must rely on available information such
as death certificates, which may be incorrect at times (Percy et al.,
1981), while others rely on clinical testing, pathological reports, or
early preclinical markers of pathology. Despite these limitations, if
the populations studied are large enough, had substantial exposure,
and had sufficient interval between exposure and study to allow for
the expression of disease, epidemiological studies have the major ad-
vantage of considering the effects of exposure in humans. Epidemio-
logical studies can often provide the basis for establishing a permis-
sible concentration for human exposure.
Epidemiological outcomes often are reported in terms of relative
risk. Relative risk is a ratio of the rate of outcome of either disease
or disability in the exposed population to that in the nonexposed pop-
ulation. Relative risk is not a measurement of risk. The relative risk
for a rare disease can be equivalent to that of a common disease and
lead to substantially less total risk. To establish a level of acceptable
exposure, information on relative risk usually must be reformulated
to understand the relationship of relative risk and risk of morbidity or
mortality. The level of risk that is acceptable is a matter of policy, not
epidemiology.
TYPES OF DATA USED IN RECOMMENDING SMACs
The preceding section described the sources of data for use in es-
tablishing SMACs. In this section, the two types of data obtained
from these sources and their importance in establishing SMACs are
described. The types are (1) dosimetry and (2) toxicity end points.
Dosimetry
Deposition of Particles, Gases, and Vapors in the Respiratory Tract
Under Microgravity Conditions
Aerosols deposit in the respiratory tract of people primarily by the
processes of sedimentation, impaction, interception, and diffusion.
Sedimentation is due to the gravitational force acting on the particles,
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and the particles may settle and deposit on the lower surfaces of air-
ways. Impaction is due to the inability of individual particles to fol-
low the curvature of air streamlines because of inertia, and the par-
ticles may hit and stick on the walls of airways. Diffusion is due to
random (Brownian) motion of small particles caused by interaction
with air molecules, which may cause a particle to move across the air
streamlines and deposit on contact with the airway wall. In a micro-
gravity environment, sedimentation will not be a mechanism of depo-
sition, and deposition will be mainly due to inertial impaction and
diffusion.
For small particles (<0.2/_m), deposition is dominated by the dif-
fusion mechanism, which is independent of gravity. Gas and vapors
also come in contact with airway walls due to Brownian motion. Thus,
the deposition of small particles, gases, and vapors in the respiratory
tract will not be significantly affected by microgravity conditions. As
the particle size increases (I-5/zm range), sedimentation becomes an
increasingly important mechanism of deposition under normal gravity
forces. Therefore, fractional deposition of particles >I _m in the
respiratory tract will be significantly less under microgravity condi-
tions. The pattern of deposition also will shift so that proportionally
more of the large particles will deposit in the tracheobronchial region,
as opposed to the alveolar region of the respiratory tract. In addition,
sedimentation is important for particles >5 #m because it greatly af-
fects the persistence of these particles in air. The concentration of
particles from 5 to 100/_m and greater inside the spacecraft will be
much higher under conditions of microgravity. These large particles
are likely to be very irritating to the eye and the respiratory tract.
Transmission of infections can increase because large droplets of saliva
and respiratory secretions remain suspended in the atmosphere for a
longer time under microgravity conditions than under normal condi-
tions. Changes in total deposition, regional deposition, and concentra-
tion of large particles in air could influence the potential health ef-
fects of particles in the space environment.
Thus, the absence of gravity makes a significant difference in par-
ticle deposition only when particles range in size from 0.5 to 2 /_m.
Diffusion will account for most deposition for vapors and for particles
smaller than 0.5/_m, and impaetion will be responsible for most par-
ticle deposition for particles larger than about 2 #m in aerodynamic
diameter.
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Pharmacokinetics and Metabolism
The evaluation of the health effects of any chemical in a given
environment is often improved by an understanding of its physiologi-
cal disposition in the body (pharmacokinetics and metabolism).
Metabolism of a chemical may lead to detoxication or may result in
metabolic activation leading to toxic effects. Since metabolic events
are usually enzyme mediated, they are driven by the concentration of
substrate available for the reaction. The concentration of substrate is
a result of the level of exposure and the pharmacokinetics of the
chemical. Modern pharmacokinetic studies are increasingly aimed at
developing dispositional models, which compare input of chemical
with outflow for the whole system as well as for individual organs.
The space station is a system that can be modeled for any given chem-
ical. The space station is a closed system with limited capacity to clear
the air of chemical vapors, while the crew contributes to the removal
of some chemicals through sequestration and metabolism. Thus, phys-
iologically based pharmacokinetic models of the disposition of inhaled
materials should be useful in helping to assess the risk of disease from
airborne toxicants in the space station.
The toxic metabolites of each chemical and factors that control the
rate at which they form are important for SMACs. It is important to
distinguish between the production of toxic metabolites in organs
where toxicity is observed and metabolism in liver where most chemi-
cals are metabolized. The relationship between metabolism in liver
and toxic effects in either liver or other organs is an important factor
because metabolism of chemicals in a liver already damaged by other
exposures is likely to differ from metabolism in a normal liver. Fur-
thermore, if toxic metabolites are moved from the liver to other or-
gans, damaged livers may alter the production of toxic responses
(Merrill et al., 1990).
To determine the possible biochemical effects of prolonged weight-
lessness on liver function, samples of livers from rats that were on
board Cosmos 1887 were analyzed for a number of key enzymes in-
volved in metabolism of compounds and xenobiotics (Merrill et al.,
1990). They observed slightly lower than normal amounts of cyto-
chrome P-450 in the livers of the flight group; this finding was similar
to that of Spacelab 3 (Merrill et al., 1987). They also observed de-
creases in the enzymes aniline hydroxylase and ethylmorphine-N-
demethylase. It is not known with certainty whether spaceflight alters
the body's ability to metabolize drugs; however, these limited results
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suggest that a change in the array of cytochrome P-450 enzymes oc-
curred in the livers of the animals. This family of enzymes is respon-
sible for the metabolism of drugs, the metabolism of a number of
natural steroid hormones and their metabolites, and the metabolism of
several compounds and mediators critical for intracellular com-
munication and regulations, e.g., prostaglandins and various growth
factors. An important function of these compounds appears to be
their role in the hematopoietic system. Therefore, the normal func-
tioning of the cytochrome P-450 system could have important impli-
cations for space biomedicine.
Toxic metabolites have been observed to be highly reactive chemi-
cally and to react with nucleic acids, proteins, or lipids to alter normal
biological function. These metabolites may induce alterations in DNA
replication or the process of transcription. Attempts to repair damage
to DNA may involve misrepair, leading to erroneous DNA replication
or function, inhibition of protein synthesis if RNA is the target, or in-
hibition of the enzyme or other activity if proteins are the target. In
addition to the formation of reactive intermediates that are metabolites
of the chemicals, metabolic activity may give rise to species of active
oxygen, which may damage nucleic acids or proteins or yield lipid
peroxidation. The effects may range from target-organ toxicity to
carcinogenesis.
Biological Markers
Recently, the concept of biological markers as indicators of ex-
posure to polluted air has been investigated (NRC, 1989b). Biological
markers within an exposed individual can indicate the degree of ex-
posure to a pollutant, the initial structural, functional, or biochemical
changes induced by exposure, and, eventually, the changes associated
with adverse health effects.
Biological markers are indicators of change within an organism that
link an exposure to polluted air to subsequent development of an ad-
verse health effect. It is convenient to divide biological markers into
three groups: (1) biological markers of exposure, (2) biological mark-
ers (early predictors) of effects of exposure, and (3) biological markers
of susceptibility to effects of exposure.
Biological markers of exposure can be thought of as "footprints" that
the chemical leaves behind after interaction with the body. Such
markers contain the chemical itself or a metabolic fragment of the
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chemical and, thus, are generally chemical-specific. Examples of such
markers are the chemical adducts formed between alkylatin8 agents
and macromolecules, such as nucleic acids or proteins, particularly
blood proteins. Another example is the presence of a volatile chemical
in exhaled air. This type of marker has been used by Wallace (1987)
to assess exposure to benzene during filling of gasoline tanks in
passenger cars, exposure to tetrachloroethylene in dry-cleaning shops,
exposure to chloroform from contaminated hot shower water in
homes, and exposure to volatile aromatic compounds in tobacco
smoke. The breath of crew members of the space shuttle or the space
station could be assayed for volatile chemicals at the end of a tour of
duty to assess exposures during spaceflights; similar measurements are
made on submariners on extended cruises (Knight et al., 1984, 1985).
Physiologically based pharmacokinetic models (Ramsey and Andersen,
1984) have been used to relate biological markers of exposure to prior
exposure conditions.
Biological markers of the effects of inhalation exposure can be any
indication of a chemically induced disease. The biological markers of
greatest interest are those that are early predictors of late-occurring
effects. Such markers would be invaluable in assessing what levels of
pollutants can be tolerated in the space station without causing irre-
versible deleterious health effects. For example, cell proliferation may
result in clonal expansion of initiated cells (Swenberg, 1989). Thus,
persistent cell proliferation could be a biological marker predictive of
an increased incidence of late-developing neoplastic lesions. Few
markers, however, have been validated as predictive of late-stage
diseases.
The third type of biological marker, markers of increased suscep-
tibility to the effects of exposure to airborne chemical pollutants, is a
potentially important, useful tool. Such markers possibly could be
used to predict which persons are more likely to be adversely affected
by space-station exposure. For example, polymorphisms related to
acetylation and DNA repair can be related to susceptibility to chemi-
cally induced tumors. Such indicators of susceptibility must be used
cautiously, however, as they pose numerous moral and ethical prob-
lems.
The appearance of metabolites in excreta have been useful in the
past and will be even more useful in the future as biological markers
of exposure, effect, and susceptibility. Metabolites that are specific
to the chemical will be most useful. When similar compounds related
to normal diet are found, the interpretation of the results may be more
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complex. Other types of biological markers that are undergoing eval-
uation include evidence of chromosomal damage and covalent binding
of reactive metabolites to DNA or proteins in circulating blood cells.
Toxicity End Points: Humans and Animals
Mortality
Short-term exposure to a pollutant at high concentrations may result
in death, which may be immediate or delayed. Mortality is a widely
used and important index in animal experiments and is also most use-
ful in epidemiological studies as an index of serious health effects. All
causes of death may be used as data for SMACs; however, certified
causes of death in humans are inaccurate at times, making it more
difficult to associate exposures with toxic outcomes.
Morbidity (Functional Impairment)
Pollutants also produce functional impairment. Most of the con-
siderations that apply to mortality as useful data also apply to mor-
bidity. It is usually much more difficult to obtain reliable information
on morbidity than on mortality. Whereas statistics of mortality are
collected routinely on whole populations, information on morbidity
usually is not. Health surveys such as the Health Interview Survey
(HIS) and Surveillance Epidemiology and End Results (SEER) (cancer
data) collect information on medical effects. Often, studies must be
initiated to answer the exposure-response questions rather than relying
on information collected for other purposes.
Clinical Signs and Symptoms
Physical examination and paying attention to signs and symptoms
can contribute to the biomedical and behavioral assessment of expo-
sure. Eye irritation and tearing, for example, are among the most
sensitive indicators of excessive exposure to oxidants. Complaints of
discomfort by exposed individuals provide an important criterion on
acceptability of pollutants. Although they may not be related to any
direct health effects, complaints of discomfort need to be considered
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as an indication of exposure and as a factor in setting acceptable expo-
sure levels.
Pulmonary Effects
The main portal of entry of air pollutants is the respiratory tract.
Respiratory symptoms, allergic sensitization, or changes in lung func-
tion provide evidence of the impact of pollutants. Spirometry is used
by far the most often of the large number of tests used to measure
changes in lung function. Widely used measures of the bellows func-
tion of the lung include the volume of air that can be expelled after
a full inspiration (the forced vital capacity); the volume that can be
expelled in a measured time, usually 1 sec (the timed vital capacity or
forced expiratory volume in l sec, FEV1); the ratio of the forced ex-
piratory capacity to the forced vital capacity (expressed as a per-
centage); lung compliance; and inspiratory and expiratory resistances.
Other useful tests are ventilation rate, gas exchange, and blood flow.
A recent report from the NRC (1989b) on pulmonary markers gives
detailed information on the use of some of these measures.
Hepatic Effects
An excellent source for reviewing the adverse effects of chemicals
on the liver is by Plaa (1991) in Casarett and Doull's Toxicology. The
liver is the single most important organ concerned with protecting the
body against the invasion of foreign, potentially toxic chemicals and,
therefore, is among the organs most vulnerable to chemical insult.
The liver avidly accumulates many chemicals, often after oral admin-
istration, leading to the so-called "first pass effect." However, accu-
mulation of chemicals and toxic responses of the liver may also occur
after inhalation or exposure via other routes.
Some chemicals, such as phosphorus, may be directly toxic to the
liver. Chemicals passing through the hepatic circulation may be acted
upon to yield detoxification products or may be activated metabolical-
ly to become more toxic chemical entities. Metabolic activation of
many chemicals leads to liver damage. Mechanisms by which liver
injury may occur include the accumulation of lipids, lipid peroxida-
tion, covalent binding of reactive metabolites to critical cellular mac-
romolecules, depletion of antioxidants such as glutathione leading to
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oxidative stress, interactive toxicological effects originating in
Kupffer cells that lead to damage in hepatocytes, disruption of cal-
cium compartmentation, and other aberrations that may lead to cell
death. The effects of chemicals may include local or generalized
lesions leading to cell death and necrosis, inflammation, fatty infiltra-
tion, cholestasis, cirrhosis, or carcinogenesis.
Underlying these injuries may be factors such as excessive alcohol
intake, diabetes mellitus, or starvation that induce increases in the
levels of cytochrome P-450IIEI, an enzyme involved in the metabolic
activation of many halogenated hydrocarbons and other chemicals to
toxicologically active or carcinogenic species. Some halogenated
hydrocarbons, such as halothane, can cause immunological responses
in liver following repeated exposure. Nutritional deficiencies may
exacerbate potential liver injury caused by chemicals such as ethanol.
Liver damage may be detected by the appearance of jaundice,
measurement of hepatic enzyme levels in circulating blood, use of
radioisotope accumulation in the liver, use of various imaging tech-
niques, or, more invasively, evaluation of liver samples obtained by
biopsy.
Reproductive and Developmental Effects
The reproductive and developmental effects of exposure to space-
craft toxicants could be either overt or subtle, and the full complement
of potential reproductive effects that could occur in the space station
is not known. Adverse effects on factors such as reproductive capaci-
ty or behavior in offspring of returned astronauts could escape detec-
tion easily against the background of human variation. These factors
need careful consideration in risk estimation. An additional factor is
that components of experimental packages are yet to be designed,
although many of the supplies that are likely to be on board are known
or will be determined. Each component merits careful consideration,
and some additional testing may be needed because reproductive and
developmental toxicity data are frequently absent from toxicological
data bases (NRC, 1984d).
The potential effects of spacecraft toxicants on reproductive out-
comes could be diverse both in nature and in mechanism. Examples
of potential adverse effects in humans can be derived in large part
from animal studies. These effects include testicular atrophy
(Melnick, 1984), transient reduction in the number of spermatozoa
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(Hanley et al., 1984), and in utero developmental problems or post-
natal abnormalities of offspring (Kimmel and Buelke-Sam, 1988). For
the purposes of this report, two assumptions may be useful concerning
reproductive and developmental toxicities: (1) in general, adverse
effects on reproduction and in utero development are threshold
phenomena, and outside of direct-acting mutagens, exposures below
certain levels have not been associated with adverse outcomes; and (2)
an excess of any contaminant may cause adverse outcomes.
Acute exposure to chemicals at levels that produce overt adult
toxicity, defined as disruption of homeostasis (Skalko and Johnson,
1987), may be considered as also capable of interfering with reproduc-
tion and development. The assumption could perhaps be made that
such severe toxicity scenarios would not occur, but if they did,
adverse effects on reproduction also would be a concern. After the
exposure had ended and normal homeostasis was established, the
reproductive system or a conceptus could have transient or permanent
sequelae that could be subtle and delayed in appearance and be
unrecognized as attributable to space-station-derived exposures.
The agents that merit special attention are those that interfere with
reproduction or development at exposure levels too low to be consid-
ered acutely toxic. The concept of target-organ toxicity can be used
to focus attention on those chemicals whose most vulnerable target is
reproductive function or in utero development. Examples of such
chemicals are ethylene glycol monomethyl ether, which has one stage
of spermatogenesis as its most vulnerable target, and thalidomide,
which, although having exceptionally low toxicity for adults, has an
as yet undiscovered aspect of in utero development as its most vul-
nerable target.
Details of test protocols for reproductive and developmental effects
testing are readily available from the U.S. Environmental Protection
Agency (EPA, 1985). Guidelines for developmental toxicity risk
assessment (EPA, 1991 ) and proposed guidelines for reproductive risk
assessment (EPA, 1988a,b) discuss interpretation of data in this area.
Neurobehavioral Effects
Some pollutants have such subtle effects on the central nervous
system (CNS) that they are detectable only by special behavioral tests
(McMillan, 1987). For the most part, these tests are designed to meas-
ure sensorimotor performance-e.g., speed, accuracy, and fine dis-
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crimination (NRC, 1984d). A large number of prevalent spacecraft
contaminants represent a potential major hazard because of their capa-
bility to alter CNS function and impair the performance of complex
tasks (Anger, 1984). There are compounds for which extrapolating
industrial threshold limit values (TLVs) to establish SMACs is inap-
propriate particularly if the industrial standards are based on gross
toxic effects of the compounds and involve discontinuous exposures.
Subtle effects, such as performance impairment, seldomly have been
considered in establishing industrial TLVs. Data on the effects of
contaminants on human performance are rarely available.
There is broad agreement, however, that screening for neurobe-
havioral toxicity can be carried out effectively with laboratory animals
by measuring motor activity, schedule-controlled behavior, and mor-
phological change in the CNS (Holson et al., 1990). The automated
measurement of motor-activity patterns provides a continuous nonin-
vasive assessment of a pollutant's effects on a stable performance
baseline over an extended time interval (Dews, 1953; Reiter, 1977;
Reiter and MacPhail, 1979). Schedule-controlled behavior, based on
procedures for programming performance antecedents and consequen-
ces, can be used to measure specific memory and learning functions
as well as sensory thresholds and reaction times (McMillan and
Leander, 1976). The measurement of morphological change in the
CNS can reveal serious neurobiological toxicity produced by environ-
mental contaminants (Spencer and Schaumburg, 1980). Such assess-
ments, however, require in situ perfusion and the use of contemporary
tissue preparation for examination by light microscopy and, prefer-
ably, electron microscopy.
Carcinogenicity
Since the first manned spaceflights almost 30 years ago, the conse-
quences of exposure to potential carcinogens (chemicals and radiation)
have been a concern. To date there is no evidence that malignant
disease occurs more frequently in astronauts and cosmonauts than in
a similar cohort of relatively young persons. However, only a limited
number of astronauts have been exposed, and to find significant ex-
cess cancer among them would imply a large increase in rates. It is
widely accepted that cancer induction is a multiphasic process with at
least three broad stages: initiation, promotion, and progression.
Clearly, exposure to potent mutagens and known initiators must be
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avoided in the space-station environment. Identification of cancer
promoters is more difficult and their implication in human-cancer
induction continues to be a source of controversy. Chemical contam-
inants in the air of the space station should be assessed by accepted
methods for their tumor-promotion potential. In general, promotion
appears to be a dose-dependent phenomenon. However, establishing
thresholds for promoters poses a significant problem for toxicologists.
The carcinogenic potential of chemical mixtures in the space-station
environment needs to be considered. The carcinogenicity of mixtures
at low concentrations is frequently assumed to be additive.
Mutagenicity
Nonlethal mutations induced by chemical or physical agents accu-
mulate with prolonged or repeated exposure conditions (long-term
effects) such as those expected on the space station. In general, a gene
mutation involves a molecular change within a single gene (point mu-
tation); a chromosomal mutation involves blocks of genes and results
from breakage (altered microscopic structure resulting in a
chromosome structural aberration) or from nondisjunction (aneu-
pioidy). Somatic-cell mutations may cause damage in the exposed
individual (carcinogenesis), whereas germ-cell mutations may cause
abnormalities in future generations.
Rapidly accumulating data show that mutations in single genes or
chromosomes are directly related to cancer initiation, promotion, and
progression (Adams and Cory, 1991; Solomon et al., 1991; Weinberg,
1991 ) and to heritable developmental defects that result in miscarriage
or offspring with one or more abnormalities (McKusick, 1990;
Borgaonkar, 1991; Rinchik, 1991; Pawson, 1991). This impressive
evidence for the impact of single mutations in humans makes impera-
tive the inclusion of mutagenic data in assessing the risks of space-
station contaminants.
Several approaches are used to gather the information needed to
determine whether genetic risks should be included in deriving
SMACs for given chemicals:
1. Mutagens expected on board. A literature search on the muta-
genicity of specific compounds would reveal whether sufficient dose
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(concentration x exposure time)-response data are available for
making risk estimates. Data from short-term mutagen assays can be
helpful in establishing permissible emergency peak concentrations as
well as maximum allowable concentrations during long-term exposure.
2. Human cell studies. The human is a good "filter" for chemicals
in air. Three cell types--the peripheral lymphocyte, the erythrocyte,
and sperm--are human cells readily accessible for analysis of gene and
chromosomal mutations and represent somatic and germ cells. In
addition to mutation, molecular biomarkers can be detected in these
cell types. Such markers are indicative of damage to crucial tool=
ecules.
• Lyraphocytes (T cells) are excellent for detecting chromosomal
changes and have been widely used for in vivo and in vitro mutagen
assays to examine structural and numerical aberrations, sister chroma=
tid exchanges, micronuclei, unscheduled DNA synthesis, and single-
strand breaks in DNA. Few data are available, however, on chromo-
somal mutation in lymphocytes of astronauts (Gooch and Berry, 1969;
Lockhart, 1974, 1977), and in light of current analytical methods, the
data are inconclusive. A fair amount of information exists, however,
about the response of lymphocytes to the conditions of spaceflight.
Analysis of blood from astronauts on the first 12 shuttle flights
revealed a significant decrease in the number of circulating lympho=
cytes (NASA, 1989). The ability of lymphocytes to be activated
(undergo DNA synthesis and cell division) by mitogens (foreign anti-
gens) is greatly diminished also or, in some cases, obliterated, as first
reported after the 1961-1969 Soyus-6, -7, and =8 flights
(Konstantinova et al., 1973) and later confirmed after the Skylab and
Spacelab DI flights (Kimzey, 1977). Although the number and func-
tion (activation capability) of lymphocytes returned to normal after
the flights, there is concern about the consequences of long=term mis-
sions.
Experiments suggesting that those effects on lymphocytes are
caused by microgravity have shown that exposure of lymphocytes to
1 g in flight (centrifuge) produced no changes when compared with
lymphocytes at microgravity (in vivo and in vitro) (NASA, 1989).
Hypergravity (I 0 g) increases the response of lymphocytes to mitogens
by as much as 500% over the level observed at I g (Lorenzi et al.,
1986). Physical stress associated with marathon running causes the
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same effects on lymphocytes as does the stress of spaceflight
(Grounder et al., 1988). Of special interest with respect to chemical
effects are reports that exposure to nitrogen dioxide at concentrations
as low as 1.0 ppm suppresses T- and B-lymphocyte responses (Fenters
et al., 1973; Maigetter et al., 1976; Richters and Damji, 1988).
• Erythrocytes and T lymphocytes are useful for detection of in-
duced gene mutations (Albertini et al., 1990). The end-point muta-
tions in erythrocytes are mainly in hemoglobin and GPA (glycophorin
A) genes and in T lymphocytes, HGPRT (hypoxanthine-guanine
phosphoribosyl-transferase) and HLA (human leukocyte antigen)
genes.
• Human sperm chromosomes can be examined by fusing them
with hamster eggs; this method has been used to study the mutagenic
effects of radiation and some chemicals (Brandriff and Gordon, 1990).
Detection of gene mutation in sperm is also possible (Wyrobek et al.,
1990). Analysis of sperm head shape and motility provides a measure
of the damage to male germ cells (Wyrobek and Bruce, 1978).
Mutations in either male or female germ cells may lead to reproduc-
tive and developmental toxicity (Kay and Mattison, 1985; Goldsmith
et al., 1984). If toxicity were to occur, the effects usually would be
difficult to detect and quantify in a given person because of variations
among individuals (e.g., sperm count), because of time and manner of
expression (e.g., congenital defects) and especially because of similar
effects occurring spontaneously in other offspring. These difficulties
should not diminish concern about their occurrence.
The induction of mutation may occur at any stage of spermatogen-
esis and result in a mutant sperm appearing immediately or years later.
In a female, all but the final stages of oogenesis are completed pre-
natally, so that at birth the ovary contains only primary oocytes. Ex-
pression of a mutation induced in a primary oocyte could be delayed
for years--i.e., delayed until the follicle containing it matures to ovula-
tion and the fertilized egg develops into a fetus or even adulthood.
• Molecular biomarkers that are primarily carcinogen-DNA or
carcinogen-protein adducts provide an extremely sensitive test of cell
interaction with chemical contaminants. Minute amounts of such
markers can be detected in DNA, e.g., 1 adduct in 109-10 l° nucleo-
tides; protein adducts in body fluids (blood, urine, breast milk, and
semen), exhaled air, and adipose tissue; and new proteins, such as
those produced by activated oncogenes (mutated genes that cause can-
cer) (Perera et al., 1991).
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Immunotoxicology
Immunotoxicology is a science that explores the effects of chemical
agents and other harmful substances on the immune system. The
immune system can be either stimulated or inhibited by xenobiotics.
Excessive stimulation can result in hypersensitivity or autoimmunity,
and suppression can be expressed by an increased susceptibility of the
host to infectious or neoplastic disease. Xenobiotic-induced immune
dysfunction has been well established for several chemicals in animals.
In some cases, the immune system has been identified as the most
sensitive target organ to detect the minimum toxic doses of a xenobi-
otic. Although one or more of the many compartments of the immune
system may be significantly suppressed, this suppression may not be
directly expressed biologically as an immune-mediated disease but
rather as a potential risk due to the reduced ability of the host to resist
natural and acquired diseases.
Animal models have been extremely valuable in identifying im-
munotoxic agents and in developing immune profiles, identifying
mechanisms of action, and alerting humans to potential health risks
associated with exposure to specific xenobiotics, either consumed as
drugs or through environmental exposure. Many immunoassays have
been validated in animals to detect drug and chemical-induced im-
munomodulation. Some of these bioassays are sensitive and predictive
in assessing immune dysfunction. Many other immune assays that
either are in the developmental stage or are not being used extensively
are likely to have application in immunotoxicology. In general, these
procedures will require additional testing and confirmation before
they can be widely accepted as validated. Although many tests are
available to screen for immunotoxicants, choice of an initial test that
evaluates T-cell-dependent antibody response permits assessment of
several compartments of the immune system concomitantly. These
procedures are easily performed, quantitative, sensitive, and economi-
cal, and they routinely detect a large percentage of the known im-
munotoxic agents.
A variety of tests are available to assess humoral and cellular im-
munity as well as nonspecific resistance in humans. A series of tests
can be performed in steps to assess immune competence in individuals
who have been exposed to an immunotoxicant or potential immuno-
toxicant. Some of these procedures parallel animal studies and require
validation prospectively in populations exposed to putative immuno-
toxicants and in control groups to ascertain their predictive value as
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immune-compromising agents. This aggressive approach will permit
use of sensitive procedures for detection of immunomodulation in
humans.
RISK ASSESSMENT
Noucarcinogen|c Effects
Toxicological risk assessment for agents without the capacity to
induce carcinogenic or mutagenic effects has traditionally been based
on the concept that an adverse health effect will not occur below a
certain level of exposure, even if exposure continues over a lifetime.
The existence of a so-called _threshold" dose is supported by the fact
that the toxicity of many agents is manifest only after the depletion of
a known physiological reserve. In addition, the biological repair capa-
city of many organisms can accommodate a certain degree of damage
by reversible toxic processes (Klaassen, 1986; Aldridge, 1986). Above
the threshold dose, however, the homeostatic physiological processes
that allow compensatory mechanisms to maintain normal biological
function may be overwhelmed, leading to organ dysfunction. Thus,
the objective of classical toxicological risk assessment is to establish a
threshold dose below which adverse health effects are not expected to
occur or are extremely unlikely.
The concept of a no-effect level was introduced by Lehman and
Fitzhugh (1954), who proposed that an acceptable daily intake (ADI)
could be calculated for contaminants in human food. This concept
was endorsed by the Joint FAO/WHO (Food and Agricultural
Organization and World Health Organization) Expert Committee on
Food Additives in 1961 and subsequently adopted by the Joint
FAO/WHO Meeting of Experts on Pesticide Residues in 1962 (cf.
McColI, 1990). Formally, an ADI is defined by the relationship
ADI = NOEL/SE,
where NOEL is the no-observed-effect level in toxicological studies
(the highest experimental dose at which effects are not observed) and
SF is the safety factor that allows for variations in sensitivity to the
test agent in humans as compared with experimental animals and for
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variations within the human population. These two sources of varia-
tion have often been accommodated through the use of a 10 x 10 =
100-fold safety factor reviewed by NRC's Food Protection Committee
(NRC, 1970).
In 1977, the NRC's Safe Drinking Water Committee reviewed the
methods that had evolved for establishing ADIs and made several
important recommendations. First, the committee proposed that
NOEL be expressed in milligrams per kilogram of body weight rather
than milligrams per kilogram of diet to adjust for dietary consumption
patterns. Second, the committee suggested reducing the traditional
100-fold safety factor to only 10-fold in the presence of dose-
response data derived from human studies. Third, the committee
proposed augmenting the traditional 100-fold safety factor to 1,000-
fold in the absence of adequate toxicity data (NRC, 1977).
Although the use of safety factors is now accepted practice in es-
tablishing exposures for noncarcinogenic effects, the NOEL/SF
approach is subject to certain limitations (Munro and Krewski, 1981 ).
Since ADI is only an estimate of the population's threshold dose, ab-
solute assurance of safety is not provided (Crump, 1984a). Smaller
experiments tend to yield larger NOELs, and hence larger ADIs, than
larger, more sensitive experiments (Mantel and Sehneiderman, 1975).
Safety factors of 10-fold that are used to account for both inter- and
intra-species variation in sensitivity cannot be guaranteed to provide
adequate protection in all cases. For these reasons, ADI should not be
viewed as possessing a high degree of mathematical precision but
should be viewed as a guide to human exposure levels that are not
expected to present serious health risks.
In 1988, EPA recommended using the term "uncertainty factor"
(UF) rather than safety factor in recognition of the uncertainty as-
sociated with ADI and relabeled ADI as a reference dose (RfD)
(Barnes and Dourson, 1988). EPA also introduced an additional modi-
fying factor (MF) to account for specific scientific uncertainties in the
experimental data used to establish RfD. The no-observed-adverse-
effect level (NOAEL) is defined as the highest experimental dose at
which no statistically significant increase in the occurrence of adverse
effects is observed beyond that exhibited under control conditions.
The RID is determined using the relationship
RiD = NOAEL/(UF × MF).
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In the present context, adverse effect is defined as any effect that
contributes to the functional impairment of an organism or that
reduces the ability of the organism to respond to additional challenges
(Dourson, 1986). When the data do not demonstrate a NOAEL, a
LOAEL (lowest-observed-adverse-effect level) may be used. A
LOAEL is defined as the lowest experimental dose at which a statis-
tically significant increase in the occurrence of adverse effects is ob-
served.
Five factors may contribute to the determination of the uncertainty
and modifying factors. These are (1) the need to accommodate human
response variability, including sensitive subgroups; (2) the need to
extrapolate from animal exposure data to humans, when human ex-
posure data are unavailable or inadequate; (3) the need to extrapolate
from subchronic to chronic exposure data, when the latter are unavail-
able; (4) the need to account for using a LOAEL, when a NOAEL is
unavailable; and (5) the need to extrapolate from a data base that is
inadequate or incomplete. Factors between 1- and 10-fold are often
used to account for each of these sources of uncertainty.
EPA has adapted the oral RfD methodology to estimate inhalation
reference concentrations (RfCs) to be consistent in setting levels of
noncarcinogenic chemicals (EPA, 1990). The inhalation RfC method-
ology departs from the oral RfD paradigm by incorporating dosimetric
adjustments to scale the exposure concentration for animals to a
human equivalent concentration.
For noncarcinogenic effects, the RfC approach should be the pri-
mary method used for setting SMACs. Uncertainty (safety) factors
between I and l 0 should be used for each source of uncertainty listed
above, depending on the nature and severity of the adverse effects.
For setting SMACs, the duration extrapolation, if any, would be in the
opposite direction from that indicated in the third source above, that
is, it would be from long-term to short-term exposure. If an expo-
sure-extrapolation approach such as Haber's rule is used and there is
considerable uncertainty as to its validity, then the exposure extrapo-
lation should be accompanied by the highest safety factor (10). In
addition to the RfC method, alternative methods such as the bench-
mark dose approach (Crump, 1984a; Chen and Kodell, 1989) should
be considered as secondary approaches to setting SMACs.
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Carcinogenic Effects
Mathematical Modeling
For carcinogenic effects, particularly those considered to be due to
genotoxic events such as alkylation of DNA, a threshold dose may not
exist. Beginning with the pioneering work of Mantel and Bryan
(1961), attempts have been made to estimate carcinogenic risks on a
precise quantitative basis. This task has involved fitting mathematical
models to experimental data and extrapolating from these models to
predict risks at doses well below the experimental range.
The probit-log dose model initially used by Mantel and Bryan
(1961) was a carryover from the tolerance distribution models used for
analyzing dose-response mortality data from acute toxicity studies.
This model was later replaced by mathematical models based on
presumed mechanisms of carcinogenesis. The mechanistic model used
most frequently for low-dose extrapolation is the multistage model of
Armitage and Doll (1961). A historical perspective on the evolution
of the multistage model has been provided by Whittemore and Keller
(1978). According to the multistage theory, a malignant cancer cell
develops from a single stem cell as a result of a number of biological
events (e.g., mutations) that must occur in a specific order. This
model predicts that the age-specific cancer incidence rate should
increase in proportion to age raised to a power related to the number
of stages in the model. This model provides a good description of
many forms of human cancer that allow for two to six stages in the
carcinogenic process.
Assuming that the rates of transition between stages in the multi-
stage model are linearly related to dose, the dose-response curve for
the multistage model is linear at low doses. Low-dose linearity is
generally assumed for chemical carcinogens that act through direct
interaction with genetic material. It is supported by theoretical con-
siderations in carcinogenesis (Krewski et al., 1989a) and by observa-
tions of the linearity of DNA binding with a number of chemical
carcinogens at low doses (Lutz, 1990). When carcinogenesis occurs
after toxic tissue injury, low-dose linearity may not be applicable, but
the assumption is widely used in applications of low-dose risk assess-
ment for regulations in the absence of clear information to the con-
trary (OSTP, 1985).
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EPA (1986) uses the linearized multistage model for low-dose ex-
trapolation. With this procedure, an upper confidence limit, q1*, on
the coefficient of the linear term in the model is obtained (Crump,
1984b). The value qz* represents an upper bound on the slope of the
dose-response curve in the low-dose region and on the excess risk
above background associated with a unit measure of close (such as
1 mg/kg of body weight per day). Only an upper confidence limit on
the low-dose slope is used by EPA for extrapolation, in part because
point estimates of this parameter are highly unstable. Linear extrapo-
lation from an upper confidence limit on excess risk obtained in the
experimental range is generally regarded as conservative in the sense
of protecting human health. It will be conservative as long as the
dose-response relationship in the low-dose region is convex, regardless
of its actual mathematical formulation (Gaylor and Kodell, 1980).
Recently, a two-stage model that incorporates tissue growth and
cellular kinetics has been proposed as an alternative to the multistage
model for cancer risk assessment (Moolgavkar and Venzon, 1979;
Moolgavkar and Knudson, 1981). Mathematical formulations of this
stochastic birth-death-mutation model have been given by
Moolgavkar and Luebeck (1990) and by Greenfield et al. (1984). The
model assumes that two genetic events (mutations), each occurring at
the time of cell division, are necessary for a normal cell to become
malignant. Allowance is made for natural growth of the target tissue
and for clonal expansion of the pool of cells that have undergone the
first mutation.
The birth-death-mutation model provides a convenient framework
for describing initiation-promotion-progression mechanisms of car-
cinogenesis. Initiating activity may be quantified in terms of the rate
of occurrence of the first mutation. The rate of occurrence of the
second mutation describes progression to a fully differentiated can-
cerous lesion. Promotional activity is measured by the difference in
the birth and death rates of initiated cells. Carcinogenic agents may
be classified as initiators, promoters, or progressors according to com-
ponents of the model that they are presumed to affect (Thorslund et
al., 1987).
Application of the two-stage model with clonal expansion in risk
assessment for putative tumor-promoting agents has been investigated
on a limited basis (Thorslund and Charnley, 1988). Before this model
can be recommended for routine application, its statistical properties
require further study, particularly with respect to predictions of risk
at low doses (Portier, 1987). In the absence of promotional effects and
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variability in the pool of normal cells, the two-stage birth-death-
mutation model is reduced to the two-stage version of the classical
multistage model.
Pharmacokinetic Considerations
Chemical carcinogens may require some form of metabolic activa-
tion to exert their effects. If metabolic activation can be characterized
adequately in terms of a pharmacokinetic model, then the dose deliv-
ered to the target should be used in place of the administered dose for
purposes of dose-response modeling and low-dose extrapolation (Hoel
et al., 1983). In general, the use of delivered rather than administered
doses may be expected to lead to more accurate predictions of car-
cinogenic risk (NRC, 1987b). Such predictions, however, may intro-
duce substantial uncertainty if complicated, physiologically based
pharmacokinetic models with 20 to 40 parameters, each subject to
uncertainty, are used for tissue dosimetry (Pottier and Kaplan, 1989,
Farrar et al., 1989).
Intermittent Exposure
Most bioassay data suitable for low-dose extrapolation reflect con-
tinuous exposure to a carcinogen, necessitating the translation of risks
calculated for continuous exposures to risks associated with short-term
or intermittent exposures. Crump and Howe (1984) developed a meth-
odology for applying the multistage model to carcinogenic risk assess-
ment when exposure to a carcinogen is intermittent. Their results
have been adapted by the Committee on Toxicology (COT) (NRC,
1986b) for setting emergency and short-term exposure guidelines for
chemicals of interest to the U.S. Department of Defense. Both multi-
stage and two-stage models have been studied with respect to age at
which exposure occurs (Kodell et al., 1987; Chen et al., 1988; Murdoch
and Krewski, 1988; Krewski and Murdoch, 1990). The results of
these investigations indicate that when an early stage in the car-
cinogenic process is dose-dependent, early exposures will be of greater
concern than later exposures. Conversely, when a late stage is dose-
dependent, late-life exposures pose a higher risk. In the context of
the classical multistage model, the potential increased excess risk from
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exposure for a fraction, f, of a lifetime at a given dose rate, d, will
never be more than k times the excess risk from full lifetime exposure
at close rate fd, where k is the number of stages in the model. (Note
that administration of daily dose d for fraction f of a lifetime yields
the same cumulative lifetime dose as administration of dose fd over
the course of a lifetime.) With the two-stage model, however, the
increased risk can be substantial when the agent of interest greatly
increases the proliferation rate of the initiated cell population.
Carcinogenic Mixtures
The interactive effects between two carcinogens have been exten-
sively studied (Krewski and Thomas, 1992). However, the existence
of synergism at low levels of exposure cannot be assessed directly.
The multistage and the multiplicative relative-risk models for cancer
predict near additivity of excess risk at low doses, even when there is
nonadditivity at higher doses (NRC, 1988c; Krewski et al., 1989b;
Chert et al., 1990). Kodell et al. (1991) recently described departures
from additivity within the context of the two-stage birth-death-
initiation model. Additivity is expected, however, at low doses for
initiators and progressors, as well as nongenotoxic promoters that may
demonstrate a threshold.
In the absence of data from experiments involving joint exposure
to multiple agents, the health risk from joint exposure to two or more
carcinogens must be based on the results of experiments with single
compounds. In the absence of evidence to the contrary, the total risk
from a mixture of carcinogens generally is assumed to equal the sum
of the individual risks of the components (EPA, 1986). This assump-
tion is consistent with the concept of a group-limit value, which
implies that individual allowable concentrations must be reduced when
they are in a mixture of chemical toxicants with the same or similar
effects to control the overall risk. Chert et al. (1990) noted that if
upper confidence limits on individual estimates of carcinogenic risk
of the same order of magnitude simply are summed as an approxima-
tion to an upper confidence limit on the total excess risk of a mixture,
the upper bound will be conservative. Using the assumption of
additivity of component risks to overcome this conservatism, Chen et
al. (1990) developed a formal procedure for calculating an upper con-
fidence limit on the total carcinogenic risk of a mixture.
ESTABLISHMENT OF SMACS 85
Interspecies Extrapolation
Quantitative methods for cancer risk assessment for carcinogenicity
must also take into account species differences. Traditionally, dose
equivalency among species has been based on body weight. However,
many physiological constants (e.g., consumption of water, food, and
oxygen) vary as a power function of body weight (NRC, 1987c).
Dourson and Stara (1983) pointed out that toxicity of many com-
pounds may be related more closely to body surface area than to body
weight (Pinkel, 1958; Freireich et al., 1966). The use of a general
power function of body weight for species conversion includes body-
weight conversion as a special case with a power of unity. Because
body surface area varies approximately in proportion to the 2/3 power
of body weight, surface-area conversion is another special case of the
general power-law relation. Based on a reanalysis of the data of
Freireich et al. (1966), Travis and White (1988) suggested that body
weight to the 3/4 rather than to the 2/3 power may be more appro-
priate for species conversion. Allen et al. (1988) found a high cor-
relation of carcinogenic potency in animals and humans but were
unable to resolve whether body weight or surface area provided a
better basis for species conversion.
If the compound is well defined in its metabolism and phar-
macokinetics, these data should be used in preference to the body-
weight to surface-area correction. The body-weight to surface-area
correction is essentially a correction for metabolic rate based on body
size. The basis of this correction is more related to rates of basal
metabolism than of xenobiotic metabolism. Thus, in the face of more
specific data on the comparative pharmacokinetics and metabolism of
the chemical in question, the correction should not be used.
Extrapolation of Animal Data to Humans
Interpretation of data derived from animal experiments requires
experienced scientific judgment in a variety of disciplines. Consider-
ation should be given to the conditions under which the data were
obtained and their relevance to conditions of human exposure under
question. How similar are the test species and the test organ to
humans and the corresponding human organ in morphology, in sen-
sitivity of response to the contaminant, and in metabolism and dispos-
ition of the contaminant? Were the observed responses of animals the
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consequences of exposure conditions to which humans may be sub-
jected?
Development of SMACs requires that animal data be extrapolated
to humans. The species most representative of humans, considering
both toxicological and pharmacokinetic characteristics, should be used
for determining the appropriate exposure limit. If data are not avail-
able on which species best represents humans, it is prudent to use data
from the most sensitive animal model to set appropriate limits.
As discussed earlier, uncertainty factors can be used when an es-
timate of the NOAEL in animals is available. In the application of
uncertainty factors, particularly susceptible individuals should be
considered. People at unusual risk might include those at risk because
of unusual physical exertion and other stresses; such risk might occur
to astronauts. Persons of suspected high susceptibility (i.e., very old
or those with known diseases) are unlikely to be space-station work-
ers, thus reducing the need for safety factors to allow for these states
or conditions. The value of the uncertainty factor also will depend on
the quality of the animal data used to determine the NOAEL. The
RfD often has been set at a level 100-fold below the NOAEL derived
from lifetime animal experiments. Larger uncertainty factors also
have been used; for example, a 1,000-fold factor usually is used to
establish an RfD when only subehronic (90-day) toxicity studies are
available. Higher uncertainty factors also may be used because of the
altered physiological status of astronauts in the space shuttle or space
station.
Conversion from animals to humans may be done on a body-weight
or surface-area basis, as discussed earlier. When available, pharmaco-
kinetic data on tissue doses also may be considered for use in species
conversion. In using toxicological data, data may have to be extrapo-
lated from those on oral exposure of animals (in milligrams per kilo-
gram of body weight) and converted to inhalation exposure of humans
(in milligrams per cubic meter of air). Two approaches are possible:
extrapolation from rat oral data to human oral dose and then to human
inhalation concentration; or extrapolation from rat oral data to rat
inhalation concentration and then to human inhalation concentration.
The first approach does not assume similar breathing rates for animals
and humans. A 70-kg man breathes air at 7-10 L/min at rest,
20 L/min when moderately active, and 40-60 L/rain when engaged in
heavy work. A resting 250-g (0.250-kg) rat breathes air at
200 ml/min (0.2 L/rain).
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To illustrate the first approach, assume that an oral dose of 1 mg/kg
of body weight per day in rats is equivalent to an oral dose of 1 mg/k_
of body weight per day in humans. A 70-kg man at rest inhales 15 m °
of air over a 24-hr period. The concentration inhaled by a 70-kg man
in 1 day is shown by the equation [(1 mg/kg)(70 kg)]/(15 m s) = 4.7
mg/m s. However, not all of what is inhaled will be absorbed. Toxi-
cokinetic information available on the uptake of the compound of
interest or on similar compounds should be used to correct the above
equation. In the above example, if only 50% of an inhaled concentra-
tion of a material is deposited or absorbed by humans, then an indi-
vidual would have to be exposed to a concentration of 9.4 mg/m s over
a 24-hr period to achieve the equivalent of an oral dose of 1 mg/kg
per day.
To illustrate the second approach, suppose that a 250-g rat at rest
inhales air at 200 ml/min or 0.288 m s over a 24-hr period. An oral
dose of 1 mg/kg in the rat is equivalent to an inhalation concentration
in the rat, as shown by [(1 mg/kg)(0.250 kg)]/(0.288 m s) = 0.87
mg/m s. For a 70-kg man inhaling 15 m s of air in 24 hr, the conver-
sion to an inhalation concentration is (0.87 mg/mS)(0.288 mS/0.250
kg)(70 kg/l 5 m s) = 4.7 mg/m s. Again, corrections should be made for
the percentage of inhaled material deposited or absorbed.
SMACs for Carcinogens
The determination of SMACs for carcinogens generally will require
extrapolation of toxicological or epidemiological data obtained under
conditions of long-term (often lifetime) exposure to periods of shorter
duration, such as 1, 30, or 180 days. Here, we illustrate how the
methods proposed by Kodell et al. (1987) based on the multistage
model can be used to set SMACs for carcinogens.
Suppose that data from a long-term animal bioassay or human epi-
demiological study have been used to arrive at an average daily life-
time exposure level, d, of a particular chemical, corresponding to a
particular lifetime excess carcinogenic risk. As reported by COT, a
lifetime risk level of 10 -4 has been used by the U.S. Department of
Defense (NRC, 1986b) to set exposure guidelines for carcinogenic
chemicals. Assume that d has been estimated with the use of any
available pharmacokinetic information to determine tissue dose, the
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linearized multistage model, and an appropriate interspecies conver-
sion factor.
Suppose that the carcinogen of interest affects only a single stage of
a multistage process and that there are up to k = 6 stages in total. Let
i (i = l, 2 ..... k) denote the index of the stage that is dose-related.
Consider the case of an astronaut exposed to a constant daily dose, D,
from age to to t I. Using results of Kodell et al. (1987, p. 340), it can
be shown that exposure to a dose,
dt _
D-
(1)
from time t o to time t1 (0 <_to < t 1 _<t) will yield the same excess risk
as a constant daily dose, d, from birth to age t, where t denotes the
time when excess risk is evaluated (usually the average human life-
time).
To illustrate, consider a three-stage process with only the first stage
dose-related, and suppose that exposure occurs at the earliest age
possible. The assumed earliest age of exposure for astronauts will be
age 25 (9,125 days), and the assumed average human lifetime will be
70 years (25,550 days). To determine the 180-day SMAC, given the
acceptable lifetime daily dose d, the value of D in Eq. l is evaluated
with k = 3, t = 25,550, t o ffi 9,125, and tl ffi 9,125 + 180 ffi 9,305. This
gives D = 115.8 d. For a 30=day SMAC, k = 3, t = 25,550, to = 9,125,
and t 1 = 9,155. Substituting these values into Eq. 1 gives D = 688.2 d.
An alternative but equivalent approach is to calculate an intermedi-
ate dose, D*, that would yield the same total exposure as the average
daily lifetime exposure level d, and then apply an adjustment factor,
f, based on the multistage model. This approach has been followed by
COT (NRC, 1986b) in performing risk assessments for the U.S. De-
partment of Defense. With this approach,
D'- _l(t_ - to), (2)
which is simply the average daily dose from age to to t 1 that would
yield the same cumulative dose as continuous exposure for a lifetime
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tO a daily dose of d. The SMAC is then defined by D*/f, where
/
t _
(3)
In the preceding example, D* would be 141.9 d for the 180-day
SMAC and 851.7 d for the 30-day SMAC. The value of f would be
1.23 for the 180-day SMAC and 1.24 for the 30-day SMAC. Con-
sidering both the multistage and two-stage models, Murdoch et al. (in
press) suggest that the value of / for astronauts between 25 and 45
years of age is unlikely to exceed a value of _2.
The case of near instantaneous exposure (e.g., single-day exposure)
at time t o to a total dose D requires separate treatment. In this limiting
case, SMACs for exposure durations of 1 day or less may be based on
the relationship
D m
dt k
{j._kl) [(k-j+ 1)do-t(t-to_-J-(j-1)_-2 (t_to)t_j÷l]t'
(4)
which applies in the case of a carcinogen that affects only the i_ stage
of a k-stage process. The corresponding adjustment factor for the
time-weighted average dose, D* = dr, is
t,) [(k-j+ 1) _- '(t - to) t-j- (]-1) _-2 (t_to)t_i.t]
f-
tk-I
(5)
It must be remembered that extrapolation from a daily lifetime ex-
posure level and conversion to an instantaneous exposure level using
Eq. 4 or Eq. 5 is an extreme case and is valid only under the assump-
tions underlying the multistage theory of carcinogenesis. As in Eq. 3,
the value of f based on Eq. 5 is unlikely to exceed 2 (Murdoch et al.,
in press).
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Use of OSHA, ACGIH, NRC, or Other Limits
There are several inhalation guidelines that can be used as sources
of information on compounds of interest. The guidelines, established
by OSHA, = ACGIH, b EPA, ATSDR, = and NRC, should be reviewed
before establishing SMACs.
The subcommittee has reviewed reports of analyses of atmospheric
contaminants detected in a variety of closed environments: seven
manned spaceflights (Mercury and Gemini series), many space-shuttle
nights, several ground-based simulated cabin atmospheres (both
manned and unmanned), nuclear submarine and Sealab experience,
and analyses of off-gas products from cabin materials. Nearly 300
compounds that could be possible space-station contaminants have
been identified.
Many of these compounds have been reviewed by the NRC's COT,
and 1- and 24-hr emergency exposure guidance levels (EEGLs) or 90-
day continuous exposure guidance levels (CEGLs) for submarines have
been recommended. The recommended EEGLs are similar to 1- and
24-hr SMACs and permit some reversible effects, such as headache
and mild irritation. The differences between the conditions for purg-
ing the atmospheres of spacecraft and of submarines must be con-
sidered. Although designing for a complete atmospheric purge by
opening the spacecraft may be possible, the need for such an emer-
gency operation must be minimized. In contrast, submarines can sur-
face to ventilate except in extraordinary circumstances.
EEGLs differ from $TELs (short-term exposure limits) recom-
mended by OSHA or ACGIH in that STELs are generally 15-min
limits to which workers may be exposed daily for many years. The l-
and 24-hr SMACs, on the other hand, are limited for infrequent
emergency exposure.
The continuous exposure guidance levels (CEGLs) recommended by
COT for submarines are ceiling concentrations designed to avoid ad-
verse health effects, either immediate or delayed, of more prolonged
exposures and to avoid degradation in crew performance that might
endanger the objectives of a particular mission as a consequence of
continuous exposure for up to 90 days.
=Occupational Safety and Health Administration.
bAmerican Conference of Governmental Industrial Hygienists.
eAgency for Toxic Substances and Disease Registry.
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ATSDR is developing documents on several industrial chemicals.
These documents provide detailed background information on the
chemicals and the basis for setting limits for those chemicals.
EPA has developed numerous cancer assessments and inhalation
RfCs that are accessible on EPA's Integrated Risk Information System
(IRIS). Both values assume a 70-year exposure, which would require
adjustment to the space scenario. EPA's cancer assessment methodol-
ogy has been described in The Risk Assessment Guidelines of 1986
(EPA, 1987).
All the documents used to establish previous industrial or public
exposure limits for airborne materials should be reviewed for perti-
nent information before establishing SMACs. The purpose of this
comparison is not to mimic the regulatory levels set by others, but to
determine if the SMACs are reasonable in light of the special needs of
NASA. The background information on how other agencies set guid-
ance levels also should be useful in setting SMACs.
Exposure to Mixtures
Individual spacecraft limits for single compounds have been estab-
lished for guidance in engineering design of atmosphere-handling
systems and represent an upper limit for each compound without re-
gard to its potential occurrence in mixtures or in the presence of other
toxicants. However, atmospheric contaminants are encountered most
often as complex mixtures, and the toxicological hazard to humans
from inhalation, especially on a long-term basis, must be assessed in
terms of permissible atmospheric loadings for these mixtures. There-
fore, individual limits must be integrated into sets of group limits to
reflect air-quality conditions judged to be safe for humans during
given exposure periods.
The spacecraft atmosphere consists of a mixture of compounds,
many of which have similar effects that are likely to be additive.
These potential additive effects must be considered in the assessment
of the toxicological hazard of contaminant mixtures. The following
guidelines for SMAC development provide for the potential summa-
tion of toxic effects of contaminants.
1. The concentration of each contaminant in the spacecraft atmos-
phere must not exceed its SMAC (1 hr, 24 hr, or 180 days) value
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expressed as a time-weighted average or as a ceiling value, as appro-
priate.
2. For each one of the groups of contaminants, a group-limit con-
cept will be utilized to evaluate the toxicological hazard of the group.
In each group, the summation, T, of the ratios of concentration to the
SMAC value of each member of the group must not exceed unity
(ACGIH, 1989). The following formula will apply when the compo-
nents in a mixture from structurally related compounds have similar
toxicological effects:
ct c, c,
* _ ÷ _ ÷... + T_; 1, (6)
suac z suaq suac, SMAC,
where Cj is the observed concentration of the i_ material and SMAC i
is the corresponding permissible concentration.
Example: Air contains 400 ppm of acetone (SMAC, 750 ppm), 150
ppm of see-butyl acetate (SMAC, 200 ppm), and 100 ppm of methyl
ethyl ketone (SMAC, 200 ppm).
400 ÷ 150 ÷ I00 , 0.53 + 0.75 ÷ 0.5 - 1.78. (7)
750 200 200
Although each individual exposure does not exceed its SMAC, the
permissible total is exceeded, and exposures must be reduced (ACGIH,
1989).
There will be situations in which the effects of exposure to mixtures
will be greater than additive, and this information must be taken into
account in setting SMACs.
Physiological adaptive responses that are important in space opera-
tion may involve muscle remodeling, loss of red-blood-cell mass
(anemia), altered nutritional requirements, and behavioral changes.
The panoply of all physiological changes considered important demon-
strates that the individual astronaut is in an altered homeostatic state.
How this altered state modifies reactions to chemicals in the space-
station environment requires additional information. With current
knowledge, the maximum allowable concentrations of airborne chemi-
cals in the closed system of space travel would have to be reduced
from permissible levels on earth. The astronaut in space is an atypical
human, particularly following extended residence in space.
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Some spacecraft contaminants may present a carcinogenic risk. In
this case, SMACs should satisfy the following guidelines:
1. The lifetime excess risk of cancer resulting from exposure to a
chemical contaminant in space for periods up to 180 days should not
exceed 10 -4 or other levels acceptable to NASA. The lifetime risk
associated with such short-term exposures may be estimated on the
basis of a time-weighted average lifetime dose in Eq. 2, divided by an
adjustment factor of f ffi2.
2. The lifetime risk for joint exposure to two or more carcinogens
should not exceed 10 -4 or other levels acceptable to NASA. Assuming
additivity of risks, the total risk is determined by summing the indi-
vidual risks.
Modification of Contaminant Toxicity by Environmental Factors
The special conditions of the space environment must be taken into
account in defining spacecraft contaminant standards. Examples of
potential interaction between contaminants and environmental factors
include the effects of increased levels of radiation on the radiomimetic
action of benzene and the effects of increased fatigue from stress
factors (e.g., noise, vibration, and weightlessness (Kaplan, 1979)).
Lung function may be different, deposition of particles is different
under microgravity conditions, the potential toxic effects of inhaled
particles on CNS active agents may be different, and the toxicity of
gases may be altered by condensation on particulates in the spacecraft.
Astronauts will be physically, physiologically, and psychologically
compromised for the following reasons: loss of muscle mass, loss of
bone mass, depressed immune system, decreased red-blood-cell mass
(anemia), altered nutritional requirements, behavioral changes from
stress, fluid shift in the body, altered hormonal status, and altered
drug metabolism.
These changes imply that an astronaut in space will be in an altered
homeostatic state and may be more susceptible to toxic chemicals.
The adaptive physiological changes that occur in microgravity may
prove to be detrimental to astronauts. For example, Merrill et al.
(1990) analyzed a number of liver enzymes from rats that had flown
aboard Cosmos 1887. They found a decrease in amounts of cyto-
chrome P-450. In addition, decreases occurred in the enzyme aniline
hydroxylase and ethylmorphine N-demethylase. Since this family of
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enzymes is responsible for the metabolism of steroid hormones and a
variety of xenobiotics, including antibiotics and drugs, this observa-
tion could have important implications for space medicine and toxi-
cology.
The changes in drug-metabolizing enzymes, immunological changes,
and other alterations could be important factors in disease susceptibil-
ity and chemical toxicity, and those should be taken into account to
recommend SMACs.
Risk assessment of chemicals is based on biological studies conduct-
ed in animals and humans on earth. It is unclear how much of the
data can be generalized to the space environment. A variety of as-
sumptions will be necessary. The quality of these assumptions can be
improved substantially as more precise human data are gained from
astronauts. Therefore, it is important to take into account the physio-
logical changes induced in the space crew and the impact of these
changes on SMAC values for various contaminants.
GENERAL APPROACH TO ESTABLISHING SMAC$
The first step in producing a document describing the SMAC for a
chemical is to collect and review all relevant information available on
the compound. Based on the review of the literature, SMACs for
different time periods are developed and a rationale is provided for
each recommendation. The next step is to review and evaluate prior
EEGLs and CEGLs, ACGIH's threshold limit values (TLVs), OSHA's
recommendation for permissible exposure limits (PELs), NIOSH's
(National Institute of Safety and Health) recommended exposure limits
(RELs), ATSDR's recommendations, and EPA's ambient air quality
standards. The intent of such a review is not to mimic the regulatory
levels set by others but to make use of all available background infor-
mation gathered by other agencies in evaluating the health effects of
the chemical of interest.
Development of l- and 24-hr SMACs for different durations of ex-
posure usually begins with providing a SMAC for the shortest expo-
sure of l hr. Values for 24-hr SMACs typically are developed by
using Haber's law when applicable. Important determinants of the
nature and severity of biological effects resulting from exposure to a
chemical are the level and duration of exposure. There has been a
general interest in assessing the extent to which the concentration, C,
of a given chemical and the duration of exposure, T, interrelate to
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determine the magnitude of the biological response, K. The overall
relationship between C, T, and K is a complex, three-dimensional
surface. However, if interest is in a particular level of biological
response, for example, K = k, the problem becomes two-dimensional.
By restricting the biological response to a particular level, k, Haber
postulated that the formula C x T ffik could be used to relate the toxic
effect of certain inhalable substances to their concentration and time
of exposure. Although the above formula, which sometimes is re-
ferred to as Haber's law, is clearly valid only for a limited number of
substances and only for certain combinations of concentration and
exposure time, it has been used to synthesize data relating concentra-
tion and time of exposure. A more general expression for examining
relationships between C, T, and k is given by C° x T b ffik, where the
exponents a and b are estimated from the data. This formula allows
for the fact that C and T do not always contribute equally to the ob-
served toxicity.
When detoxification or recovery occurs and data are available on
24-hr exposures, these factors must be taken into account in modify-
ing Haber's law (C x T = k). Haber's law is inappropriate for materi-
als, such as ammonia and NO2, that have been shown to be more toxic
with high concentrations over short periods. High concentrations of
particulates also have been shown to overload normal host defense
systems, making predictions from such data bases unreliable for long-
term, low-level exposures. Consequently, caution must be exercised
in using even the general expression for C, T, and k when evaluating
exposure conditions that are likely to result in comparable effects in
laboratory animals and humans.
The approach to establishing 1- or 24-hr SMACs is judged on a
substance-by-substance basis. For substances that affect several organ
systems or have multiple effects, all end points--including reproductive
(in both sexes), developmental, carcinogenic, neurotoxic, respiratory,
and other organ-related effects--are evaluated, the most important or
most sensitive effects receiving the major attention. For the many
compounds, such as upper respiratory tract irritants, for which there
are reliable human data and a high degree of confidence that effects
from a single exposure will be reversible, then NASA may establish
exposure limits directly from the available data. For those compounds
that have few human data but sound animal data and effects that are
likely to be reversible following a single exposure, a species extrapola-
tion factor may be employed, the magnitude of which will depend on
the quality of the data.
96 GUIDELINES FOR DEVELOPING SMACS
In the absence of better information, a safety factor of 10 is sug-
gested for 1- and 24-hr SMACs when only animal data are available
and extrapolation from animals to humans is necessary for acute,
short-term effects or when the likely route of human exposure differs
from that of a relevant experiment. With carcinogenic chemicals, the
SMAC is set so that the estimated risk of a neoplasm in the upper 95%
confidence limit is no more than 1 in 104 or some other risk acceptable
to NASA.
SMACs do not represent a sharp dividing line between safe and
unsafe concentrations. Some people are expected to be affected ad-
versely when SMACs are exceeded. However, some persons may be
affected adversely even when SMACs are not exceeded. When expo-
sure lasts longer than 24 hr, the 24-hr SMAC no longer applies, and
appropriate measures must be taken to comply with the concentration
implied by the corresponding 7-day, 30-day, and 180°day SMAC
values.
The 30- and 180-day SMACs are generally 0.01-0.1 times the 24-hr
SMAC for noncarcinogenic substances. When detoxification is sub-
stantial, a division by 10 may be more appropriate. When detoxifica-
tion is not evident or is slow, a division by 100 or more may be more
appropriate. When the substance accumulates in tissues, as do halo-
genated biphenyls and metals, even larger safety factors may be used.
In other cases, lower safety factors may be applied, depending on the
data. The choice within these general guidelines must be determined
for each material separately. When data from chronic studies are
available, they are used to derive 180-day SMACs, applying safety
factors as needed. With carcinogenic chemicals, an estimate of risk is
provided for the recommended SMACs. When a substance is known
to cause an effect that will be aggravated by microgravity, additional
safety factors should be used.
The suggested format for a SMAC document is shown in
Appendix 1. The conversion factors and the reference values used in
establishing SMACs are listed in Appendixes 2 and 3, respectively.
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Appendix 1
FORMAT FOR SMAC DOCUMENTS
Background Information
Physical and Chemical Properties
Occurrence and Use
Summary of Toxicity Information
Effects on Humans
Effects on Animals
Acute, Subacute, and Chronic Exposures
Mutagenicity, Teratogenicity, and Carcinogenicity
Pharmacokinetics
Absorption and Distribution
Metabolism and Excretion
Inhalation Exposure Levels (from other sources, such as TLVs from
ACGIH and PELs from OSHA standards)
Committee Recommendations (emergency exposure guidance levels:
current and prior COT recommendations and rationale for new
numbers)
Recommendations for Future Research (when applicable)
Tables
References (and cutoff date for published papers)
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Appendix 2
CONVERSION FACTORS
1. From gas in gas to ppm by volume, at 25"C and 760 mmHg:
m# x 10 -3 - m&
m s L
mg x 24,450
- ppm
m 3 (molecular wt)
tun of&as ppm
tool of air
% by vo/ume x 10 -4 = ppra
2. From gas, liquid, or solid in liquid to ppm by weight:
mg. ppm
L
mo___llx molecular wt x 103 - ,n____g
L L
3. From amount received by inhalation to amount ingested:
m...&8x volume of inspired in air m s x % retention]lO0 -mg
7113
111
PRECEDI_G PAGE _3f ....
bJLh,.'e::.:.r
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4. From concentration in diet to ingested dose:
ppb/n d_ x 10_ - ppm /n d/et
ppm/n diet- mS//_ind/et- _$/S/nd/et
n,_/hr diet x food/atate, _day. me,/h_/day
body weight, h_
5.From percent to concentration:
&_ = g/xw ml
Appendix 3
REFERENCE VALUES USED BY COT
Daily water intake, adult human
Daily food intake, rat
2L
20 g
Man Woman
Body Weight, kg
Blood volume, L
Total blood weight, g
Red-cell volume, L
Red-cell weight, g
Plasma volume, L
Plasma weight, g
Urine volume, L/day
Surface area, cm _
Minute volume, resting,
L/rain
Minute volume, light
activity, L/rain
Volume inspired air,
8-hr workday, m s
Volume inspired air,
rest all day, ms
Volume inspired air,
moderate activity
plus sleep, ms
70
5.2
5,500
2.2
2,400
3.0
3,100
1.4
18,000
7.5
20.0
9.6
15
20
58
3.9
4,100
1.35
1,500
2.5
2,600
1.0
16,000
6.0
19.0
9.1
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